[{"article": "Clinical Outcomes of Transplanted Modified Bone Marrow-Derived Mesenchymal Stem Cells in Stroke: A Phase 1/2a Study.\n\u201cThe recovery some patients showed was not just minimal, it was significant,\u201d said Steinberg, who has researched stem cell therapies for more than 15 years.\n\u201cWhat surprised us most was the remarkable recovery some patients had,\u201d Dr. Gary Steinberg, professor and chair of neurosurgery at Stanford, told Medical Daily, \u201cWhile we had hoped for that, we didn\u2019t really expect it.\nFurthermore, there were no life-threatening effects linked to the procedure used to administer them.\nRecently, researchers from the Stanford University School of Medicine have made it their mission to improve these outcomes.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Because the story includes an interview with the lead researcher\u2013with quotes not found in the news release\u2013this is Satisfactory. However, that\u2019s about the only information in the story not found in the news release, so this is a barely passing scenario.", "answer": 1}, {"article": "They find that there are real deleterious side effects but that they are manageable, and conclude the drug is worth using under the proper circumstances,\" he said.\nOverall, Avastin, like several other targeted agents have led to therapeutic advances in lung cancer, he added.\nHowever, several issues remain to be determined, including the optimal dose and the role of maintenance therapy with Avastin, he said.\nOverall, 3 percent of the patients died due to adverse events associated with Avastin.\nIt's possible the FDA will withdraw approval of Avastin as a breast cancer treatment.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "\u00a0Does not appear to rely on a news release.", "answer": 1}, {"article": "October 2010, 16(10): 1079-1088. doi:10.1089/acm.2009.0634.\nIndividuals should consult with a professional massage therapist to determine the best massage therapy approach for their specific needs.\nRegular massages have been shown to make the immune system stronger, according to studies.\nImmediate massage benefits included reduced anxiety while the long-term impact increased serotonin values, natural killer cell numbers and lymphocytes,iii which work to strengthen the immune system and cognitive function during sickness.\nBy meeting or exceeding state training requirements, ascribing to a code of ethics and participating in continuing education, American Massage Therapy Association massage therapists are appropriate additions to any wellness regimen and create specialized approaches based on individual conditions, fitness and goals.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "We feel the language was unjustifiable due to its ambiguity, and some wording bordered on sensational.\nPhrases such as \u201csignificant changes,\u201d \u201crapid responses\u201d and \u201cimmediate massage benefits\u201d don\u2019t inform the reader if no scale is given. Some additional examples of inappropriate language:", "answer": 0}, {"article": "His own previous research indicates that cannabis was used as early as 1800 B.C.\nGW Pharmaceuticals, a company that is developing cannabidiol medicines, helped subsidize the study.\nThe study was a randomized, double-blind, placebo-controlled human trial, which is considered the gold standard test for any new medicine.\nShe was not involved in the new study.\nHe noted that generating more evidence of effective use is \"a good thing.\"\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not rely on a news release.", "answer": 1}, {"article": "Mihai G. Netea, PhD, professor in the Department of Internal Medicine at Radboud University Medical Center in the Netherlands, says of this study, \"The clinical effects and the proposed mechanism demonstrated are exciting and add to the emerging consensus that the BCG vaccine can have a lasting and valuable impact on the immune system.\nThe MGH team's findings set the stage for further testing of BCG administration, including the FDA-approved phase 2 study currently underway, testing multiple BCG doses in a large group of participants with longstanding type 1 diabetes.\nBut by the end of that short, 20-week trial, there was no reduction in HbA1c, the established measure of blood sugar levels over time.\n\"In addition to the clinical outcomes, we now have a clear understanding of the mechanisms through which limited BCG vaccine doses can make permanent, beneficial changes to the immune system and lower blood sugars in type 1 diabetes.\"\nLong-term follow-up of participants in clinical trials of a generic vaccine to reverse advanced type 1 diabetes finds significant clinical benefits, including restoration of near-normal blood sugar levels.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "There is no blatant sensationalism.\nHowever, claiming \u201cclinical validation of the potential\u201d of the vaccine to do something seems like weasel words, particularly in the context of a phase 1 trial.", "answer": 1}, {"article": "Jan. 4, 2013 -- A new study from Australia may offer a new way of identifying people at risk of glaucoma years before vision loss happens.\nThe study appears in the latest issue of the journal Ophthalmology.\nThose with the narrowest vessels at the beginning of the study were four times more likely to have developed glaucoma a decade later.\nBut they added that blood pressure and other factors that can contribute to vessel size would need to be considered.\nEarly detection is key, but without regular eye exams, most people don\u2019t know they have a problem, says ophthalmologist Andrew Iwach, MD.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It does not appear that the story relied solely or largely on a news release.", "answer": 1}, {"article": "In a study suggesting that red wine might be the next big thing in breast cancer prevention, a study has found that women who drank just under two servings of red wine daily experienced hormonal changes that mimic the effects of a drug used to prevent malignant breast tumors from coming back.\n\nThe study, published Friday in the Journal of Women's Health, found that consuming the same amount of white wine did not have the same effect in premenopausal women participating in the study.\n\nWomen intent on warding off breast cancer have been warned about alcohol consumption: as recently as November, a study found that women who consumed as few as three servings of alcohol a week increased their risk of developing the disease, which strikes one in eight American women at some point in life.\n\nWhite wine and other alcoholic beverages are believed to promote the conversion of androgens--\"male hormones\" such as testosterone, which circulate in all women's blood--into estrogen. And the greater a woman's lifetime exposure to estrogen--whether her own or estrogen that comes from medication or environmental sources--the higher her risk of developing breast cancer.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story didn\u2019t rely solely or largely on a news release.\nEven the Cedars-Sinai news release, though, included more caveats than the story did.\u00a0 The news release stated:\n\u201cthat large-scale studies still are needed to evaluate the safety and effectiveness of red wine to see if it specifically alters breast cancer risk. \u00a0He cautioned that recent epidemiological data indicated that even moderate amounts of alcohol intake may generally increase the risk of breast cancer in women. Until larger studies are done, he said, he would not recommend that a non-drinker begin to drink red wine.\u201d\nA bit different than the story putting \u201cI\u2019ll drink to that\u201d in the headline, \u201cmight be the next big thing in breast cancer prevention\u201d in the first sentence, and signing off with with \u201cL\u2019chaim!\u201d", "answer": 1}, {"article": "There are three types of omega-3 fatty acids: a-linolenic acid (ALA), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).\n\"There is evidence that both omega-3s from plants and marine sources are protective against cancer and we wanted to determine which form is more effective.\"\nBased on the doses given in the study, Ma said humans should consume two to three servings of fish a week to have the same effect.\nBesides certain foods containing EPA and DHA, supplements and functional foods, such as omega-3 eggs or DHA milk, can offer similar cancer prevention effects, he added.\nProf. David Ma has discovered that marine-based omega-3s are eight times more effective at inhibiting tumour development and growth.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The news release gives premature medical advice to \u201cchoose omega-3s from fish over flax for cancer prevention\u201d and \u201cconsume two to three servings of fish a week,\u201d and suggests without evidence that \u201comega-3s will likely be beneficial for other types of cancer.\u201d It veers even further astray by conveying a researcher\u2019s view that \u201csupplements and functional foods, such as omega-3 eggs or DHA milk, can offer similar cancer prevention effects.\u201d", "answer": 0}, {"article": "Olive oil users may, for example, have higher incomes, eat better overall or exercise more often than people who never use the oil.\nAnd after they did, olive oil was still linked to a lower stroke risk.\nWhat\u2019s needed, he said, are clinical trials where people are randomly assigned to use olive oil or not, then followed over time to see who suffers a stroke.\nSuch clinical trials are considered the \u201cgold standard\u201d of medical evidence.\nThe findings, according to Scarmeas, argue for more research into olive oil\u2019s potential benefits against not only heart disease, but stroke and other neurological diseases as well.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It\u2019s clear the story did not rely on a news release.", "answer": 1}, {"article": "The study, conducted in conjunction with the University of Washington, involved 56 men who were assigned to receive one of three types of gels: one gel containing both testosterone plus a gel containing one of two doses of the synthetic progestin; or a gel containing testosterone on its own plus a \"placebo\" gel with no progestin.\nOne important and unanswered question is what the long-term side effects of this regimen might be.\nAnother question is how reversible this would be in terms of restoring sperm counts, Alukal said.\nBecause the new study was presented at a medical meeting, the data and conclusions should be viewed as preliminary until published in a peer-reviewed journal.\nThere's more on contraception at the American College of Obstetricians and Gynecologists.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story wasn\u2019t based on a press release. Rather, we wonder if it was based primarily on a 335 word abstract published on the Endocrine Society\u2019s website.", "answer": 1}, {"article": "reflect problems that cause squeaking, which it contends occurs in less than 1 percent of implants.\nWhatever the actual frequency, some investigators who have looked at the problem say the squeaking seems to be associated with extreme flexing of the ceramic implants, but exactly how is unclear.\nAlready, dozens of patients have elected to endure subsequent surgeries to replace the noisy hips.\nDr. Bried, who implanted Mr. Mueller\u2019s hip last year, said he was concerned that squeaking might be \u201ca harbinger of something similar.\u201d\n\nMr. Mueller said Dr. Bried had told him to consider getting the hip replaced \u201csooner rather than later.\u201d\n\nStryker says such fears are overblown.\nDr. D\u2019Antonio, whose longstanding role in Stryker\u2019s product development efforts earned him $1.1 million in consulting payments from the company last year, said he had implanted 400 Tridents since the clinical trials began in 1996.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story cites several sources and does not appear to rely solely or largely on a news release.", "answer": 1}, {"article": "Our intention is to provide a plan for moving forward with an emphasis on patient safety.\u201d\n\nThe clinical results did not address a key issue for patients and regulators: whether Beloranib triggered the blood clotting that resulted in two patient deaths last year.\n\u201cAs of today, we have no evidence to suggest that Beloranib by itself can cause blood clots,\u201d Hughes said.\n\u201cThis is the first demonstration of a clinical benefit against two of the major issues that affect this patient population.\nZafgen has not identified the patients who died or said at which of 14 US trial sites they were taking the drug.\nThomas E. Hughes, chief executive of Zafgen, said the Boston company will use the data to prepare a \u201crisk-mitigation\u201d plan to help persuade the Food and Drug Administration to lift its so-called clinical hold on the late-stage trial, allowing it to resume.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There\u2019s enough original reporting that we can be sure the story isn\u2019t based entirely on a news release.", "answer": 1}, {"article": "Professor Shepstone added: \"This is the first trial to show that a community-screening approach based on the FRAX fracture risk tool is both feasible and effective.\nHalf of the women were screened to compare screening with routine care.\nThe team used a University of Sheffield developed tool called FRAX, which predicts the probability of a hip fracture or a major osteoporotic fracture (a hip, spine, upper arm or lower arm fracture), to identify older women at high risk.\nMortality at one-year post-fracture is approximately 20 per cent.\"\nAmong those screened, treatment was subsequently recommended for one in seven women deemed at high risk of hip fracture.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "No unjustifiable language was identified.", "answer": 1}, {"article": "Labor may be induced by breaking the amniotic sac or by using hormones called prostaglandins or medication such as oxytocin, which can set off contractions.\nShe called it \u201cconcerning and rash\u201d for doctors at the meeting to make \u201cbroad conclusions\u201d that \u201ccould potentially affect at least 3 million women a year in the United States alone.\u201d\n\nNorwitz said that the presentations were evidence-based.\n\u201cThere are anywhere between 25,000 to 30,000 stillbirths a year in the United States.\u201d\n\nLockwood and Norwitz\u2019s support for induction at 39 weeks not only surprised many of the doctors at the session, it also upset those who believe less intervention is the safest route for mother and baby.\n\u201cIt\u2019s obvious that a blanket policy of 39-week inductions would not affect all of the stillbirths that happen before 39 weeks,\u201d Dekker said, adding that the CDC report concludes, \u201cDespite intensive investigations, for a substantial number of fetal deaths a specific cause of death cannot be determined.\u201d\n\nAnd, Dekker said, the public has the misconception that inductions are simple, noninvasive procedures.\nDekker said there were flaws in the research showing that women who received elective induction had lower rates of Caesarean delivery.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story published on June 27, 2016 refers to a session at a conference that occurred in May. It is not clear whether the reporter attended the meeting and spoke to the participants or merely relied on second-hand reports of the session. However, the story includes quotes from what appear to be interviews with several sources.", "answer": 1}, {"article": "Consultant hematologist John Snowden said: \u201cThe immune system is being reset or rebooted back to a time point before it caused MS ...\nThis is not a technology you can patent and we have achieved this without industry backing.\u201d\n\nEmma Gray, the head of clinical trials at the MS Society, said: \u201cOngoing research suggests stem cell treatments such as HSCT could offer hope, and it\u2019s clear that in the cases highlighted by Panorama, they\u2019ve had a life-changing impact.\n\u201cThe MS Society has recently funded a study looking into the impact of HSCT on the immune system and we\u2019d like to see larger trials in this area.\nI\u2019d rather have done 10 rounds with Mike Tyson.\u201d\n\nRichard Burt of Northwestern University in Chicago, who carried out the first HSCT for MS in 1995 and is coordinating the international trials, told the BBC: \u201cThere has been resistance to this in the pharma[ceutical] and academic world.\n\u201cWe want people to be aware that HSCT is an aggressive treatment that comes with significant risks.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "We couldn\u2019t find any news release that could have spawned this story. However, its use of almost identical sources and direct quotes to those of a BBC News story that was posted earlier on the same day leads us to question the nature of the material used by the newspaper. The BBC claimed that it had been given \u201cexclusive access\u201d to the patients in this clinical trial, but that does not explain\u00a0the details\u00a0in The Guardian. Given the troubling overlap between these stories, we\u2019re reluctant to award a Satisfactory since the story does seem at the very least to have borrowed text either from the BBC or an unknown source news release. We\u2019ll rate this Not Applicable, which means we\u2019re neither crediting nor penalizing the story.", "answer": 2}, {"article": "Ginger, an herb, is found in supplements and in many foods such as ginger snaps and Asian dishes.\nBut for now, she said, \"if you want to embrace ginger because you like the taste, go ahead,\" but there's no solid evidence that it prevents colon cancer.\nIf more funding becomes available, the researchers hope to launch a larger study, Zick said.\nPrevious research in animals has suggested that ginger can reduce inflammation but isn't potentially toxic to the stomach like aspirin, Zick noted.\nHowever, more study needs to be done, and the researchers aren't yet recommending that people head to the supplements' aisle or start gobbling up more ginger at meal times.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There\u2019s no evidence that the story relied solely on a news release.", "answer": 1}, {"article": "Dieters who go vegetarian not only lose weight more effectively than those on conventional low-calorie diets but also improve their metabolism by reducing muscle fat, a new study published in the Journal of the American College of Nutrition has found.\nHowever, we also showed that a vegetarian diet is much more effective at reducing muscle fat, thus improving metabolism.\nLosing muscle fat improves glucose and lipid metabolism so this finding is particularly important for people with metabolic syndrome and type 2 diabetes, says lead author, Dr. Hana Kahleov\u00e1, Director of Clinical Research at the Physicians Committee for Responsible Medicine in Washington DC.\nBoth diets were restricted by 500 kilocalories per day compared to an isocaloric intake for each individual.\nDr. Kahleov\u00e1 said: \"Vegetarian diets proved to be the most effective diets for weight loss.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release doesn\u2019t rely on sensational, unjustified language.\nIt does, however, overstate the findings of the research. The first sentence reads:\n\u201cDieters who go vegetarian not only lose weight more effectively than those on conventional low-calorie diets but also improve their metabolism by reducing muscle fat, a new study published in the Journal of the American College of Nutrition has found.\u201d\nThis is a definitive statement and at no point in the rest of the release does it state\u00a0that additional research is needed to confirm the findings.", "answer": 1}, {"article": "For more information, see www.scripps.edu.\nThe antibiotic has been prescribed by doctors for 60 years, and bacteria are only now developing resistance to it.\nThe original form of vancomycin is an ideal starting place for developing better antibiotics.\nEven if the process isn\u2019t streamlined, Boger believes the new vancomycin\u2019s lifesaving powers make its production valuable.\n\u201cOrganisms just can\u2019t simultaneously work to find a way around three independent mechanisms of action.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "When saying that research has given a drug \u201cnew superpowers,\u201d one expects to find robust and overwhelming data that demonstrates the efficacy of the relevant drug in a clinical setting. That is not the case here. And, frankly, it is difficult to think of a context in which a drug could be accurately described as \u201cmagical.\u201d The language is over the top, particularly for a modified drug \u2014 even a promising one \u2014 that is this far removed from clinical use.", "answer": 0}, {"article": "A study of a proposed diabetes drug, Januvia, from Merck & Co. showed it lowered a key measure of blood sugar when taken in combination with another common diabetes drug.\n\nThe study, due to be presented Thursday at the European Association for the Study of Diabetes in Copenhagen, involved 1,056 patients diagnosed with Type 2 diabetes who hadn't previously been treated with diabetes medications.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It is unclear where the author obtained the information. The reuslts have not been presented as yet and the authors were not quoted. It appears that the source was the drug company; no information was given from experts in the field to place this new agent in context. Nonetheless, because we can\u2019t be sure the story relied solely or largely on a news release, we rate it N/A. ", "answer": 2}, {"article": "\"We don't want to treat any man unnecessarily with that type of treatment.\nThese findings are good news for some men, since the effects of short term of hormone therapy are reversible, D'Amico said.\nSo, that brings into question how much, if any, hormone therapy is needed, he added.\nThe hormone therapy started two months before radiation.\nOverall, hormone therapy reduced the risk of dying from prostate cancer over 10 years from 8 percent to 4 percent, Jones said.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Does not appear to rely solely on a news release.", "answer": 1}, {"article": "Malignant mesothelioma is an aggressive and almost uniformly fatal tumor caused primarily by exposure to asbestos.\nThe ONCOblot\u00ae test is based on more than 20 years of basic research.\nA 510(k) application is being prepared for submission to the FDA to register the ONCOblot test as a medical device.\nMorNuCo Laboratories is elated to share these results with the public, as early detection is widely considered the corner stone of an effective strategy to reduce cancer-related deaths.\nThe ONCOblot Test is CLIA registered and meets all current FDA regulations as an LDT.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "There are only nine sentences in this release, yet there is room to boast of \u201cexciting results,\u201d \u201cexciting sign of progress\u201d and an \u201cexciting new chapter\u201d that the company is \u201celated to share.\u201d While the study results may well be exciting to some researchers who are planning clinical trials of early treatments for rare mesothelioma cancers, there is nothing in this study that is truly \u201cexciting\u201d to people worried about their personal risk of developing mesothelioma. The release dangles false hope in front of people exposed to asbestos by pushing the popular myth that \u201cearly detection is widely considered the corner stone of an effective strategy to reduce cancer-related deaths\u201d.\nAs this online primer summarizes, the triple stumbling blocks of lead time bias, length bias and overdiagnosis stand between this study and any real understanding of whether the news may ever be exciting to people worried about the consequences of exposure to asbestos.", "answer": 0}, {"article": "Outside of heart attacks, doctors are often too quick to use a common $20,000 procedure to treat patients suffering from coronary artery disease, a new study suggests.\n\nAbout 600,000 angioplasty procedures, which almost always involve placement of a tiny metal tube called a stent, are done in the U.S. each year. Roughly 70% of these procedures are performed on patients suffering symptoms of a heart attack and aren't medically controversial. But the remainder are done on stable patients who are suffering mild symptoms or no symptoms...", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It\u2019s clear that this story employed independent reporting to tell the story.", "answer": 1}, {"article": "DARIEN, IL - Nov. 16, 2017 - A new study shows that positive airway pressure (PAP) therapy improves quality of life measures in people who have obstructive sleep apnea.\nThe study is published in the Nov. 15 issue of the Journal of Clinical Sleep Medicine.\n\"This information will guide clinicians in terms of expected quality of life outcomes with sleep apnea treatment.\"\nThe improvements were more robust in those who were adherent to PAP therapy.\nThe study involved 2,027 patients with sleep apnea who began PAP therapy between Jan. 1, 2010, and Dec. 31, 2014.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "No unjustifiable or sensational language here.", "answer": 1}, {"article": "But high blood pressure also appears to increase a person's risk of developing Alzheimer's disease, which is associated with the accumulation of plaques and tangles in the brain.\nKoroshetz's campaign is getting some help from the Alzheimer's Association.\nAt least two large studies have revealed an alarming trend among stroke patients, Koroshetz says.\nHe is responsible for the institute's public health campaign called Mind Your Risks.\nKoroshetz is using all of these approaches.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The Alzheimer\u2019s Association website is promoting its upcoming July annual meeting, but there was no news release specifically addressing the content of this story.", "answer": 1}, {"article": "\"Nothing happens,\" he told Stahl.\nHe managed to intrigue Dr. Steven Curley, a liver cancer surgeon at MD Anderson Cancer Center in Houston.\nHe tried it out on a hot dog, injecting it with a metal solution.\nBut Kanzius wasn't happy with all the time it would take Curley to get through the usual human clinical trials and approval by the FDA.\nStahl remarked.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Stahl and the \"60 Minutes\" team apparently created this puffery without the assistance of press agents.", "answer": 1}, {"article": ".\nBut now, according to a study published Sunday in the New England Journal of Medicine, there appears to be a new, much less invasive way of determining whether a growth is malignant.\nThe current advance was a long time in coming and shows the difficulty of bringing research from the lab to the consumer.\nSpira said the initial discovery was made 12 years ago, but he couldn't find any private group willing to put up the millions of dollars needed to conduct studies, work through the government and academic regulatory process and bring his idea to market.\nThe next logical question is whether those changes might be detected early enough to predict and prevent lung cancer.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It\u2019s unclear where the bulk of the article\u2019s information came from beyond an interview with the test\u2019s developer, a professor of computational biology and researcher at Boston University\u2019s medical school. Veracyte, the company that bought the test, issued a release via\u00a0PR Newswire and made researchers and company officials available to reporters in a conference call. If the story relied on those sources, it should have noted that was the case. Inclusion of an independent source would have erased any doubt in our minds as to the story\u2019s reliance on any news release. But since we can\u2019t tell either way where the information came from, we\u2019ll rate this Not Applicable.", "answer": 2}, {"article": "Some research has suggested a link between lower levels of insulin in cerebrospinal fluid and the formation of plaques often found in the brain tissue of people with Alzheimer\u2019s.\nThe research described in Quick Study comes from credible, peer-reviewed journals.\nCAVEATS The study involved a relatively small number of participants and lasted a short time; a larger and longer study would be needed to adequately test effectiveness and safety.\nWHO MAY BE AFFECTED ?\nNonetheless, conclusive evidence about a treatment's effectiveness is rarely found in a single study.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not rely excessively on this news release.", "answer": 1}, {"article": "Previous studies have found that aspirin users enjoyed a lower risk of colon cancer; a trial published earlier this year concluded that people who take a daily aspirin have as much as a 46% lower risk of colon, lung and prostate cancers, compared with non-users.\n\u201cGiven the high skin cancer incidence and the widespread and frequent use of NSAIDs, a preventive effect of these agents may have important public health implications,\u201d the authors, led by Sigrun Alba Johannesdottir from Aarhus University Hospital in Denmark, wrote.\nYou can also continue the discussion on TIME\u2019s Facebook page and on Twitter at @TIME.\nIt\u2019s not the first study to show a potential anticancer effect of aspirin and other similar painkillers \u2014 a class of medications known and nonsteroidal anti-inflammatory drugs, or NSAIDs.\nHowever, the researchers didn\u2019t have information on other key skin cancer risk factors like exposure to UV radiation.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story acknowledges lifting a quote from this press release, but there\u2019s no evidence that the story used any other content from the release. We can\u2019t be sure about this one, so we\u2019ll rate it not applicable.", "answer": 2}, {"article": "What happens with age-related macular degeneration is that the center of the retina deteriorates, and people gradually lose sight.\nThis is why the telescope is implanted in only one eye.\nShe was not Orr's doctor.\nAnd 75 percent of them, like Orr, had major improvement.\nColby says that's also why patients need to learn to use the implanted telescope eye for near activities.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "This story does not rely on a news release.", "answer": 1}, {"article": "The researchers conclude that the added sensitivity of cotesting versus HPV alone for detection of treatable cancer affected extremely few women.?\nThis remains the most extensive experience of HPV testing incorporated into routine screening in the world.\nHowever, reports of rare HPV-negative, Pap-test-positive cancers are motivating continued use of both tests (cotesting) despite increased testing costs.\nBut improved screening methods have also introduced some confusion, even controversy.\nGiven the rarity of cancers among screened women, the contribution of the Pap test to screening translated to earlier detection of at most five cases per million women per year.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "We found no unjustifiable language.", "answer": 1}, {"article": "It is high in polyphenols--compounds with strong antioxidant activity that in test-tube and animal models show anticancer and heart-protective effects.\nThere's a growing body of research to suggest that both are probably good for you.\nGood clinical studies are few, however, and although I and other physicians tell our patients to drink green tea, there hasn't been any definitive proof of the value of that advice.\nWe've heard a lot about the health benefits of tea, especially green tea.\nThat's why I was so interested in a report last week in the Journal of the American...\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "This article does not appear to rely on a press release.", "answer": 1}, {"article": "\"Once injected into a patient's artery, many stem cells are lost due to the combination of tissue blood flow, which can wash out stem cells, and cardiac contraction, which can squeeze out stem cells.\n\"Stem cell therapies show great promise as a treatment for heart injuries, but 24 hours after infusion, we found that less than 10 percent of the stem cells remain in the injured area,\" Dr. Eduardo Marban, director of the Cedars-Sinai Heart Institute in Los Angeles, said in a news release from the institute.\nMarban and his wife, Linda, are founders of a company that has filed patents for the techniques.\nThe study was published online April 8 in the journal Circulation Research.\n\"Tissue viability is enhanced and heart function is greater with magnetic targeting,\" Marban said.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story states that its source is a Cedars-Sinai Heart Institute news release. There\u2019s no sign of independent reporting or vetting of the claims. ", "answer": 0}, {"article": "An epileptic seizure occurs when large groups of neurons in the brain begin firing uncontrollably, disrupting the balance of electrical activity and causing changes in mental function, motor function and behavior.\nHalf of all patients are children.\n\u201cThis is a novel finding,\u201d Dr. Vezzani said in an interview.\nBut there are dangers to this approach.\nThe drug is now the subject of a Phase 2 trial involving 400 patients.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not rely on a press release.", "answer": 1}, {"article": "It's what goes into making the J-shaped spine that matters: \"You have to use muscle strength to get your spine to look like a J shape,\" he says.\nAnd it doesn't bother her that the method hasn't been tested in a clinical trial.\nBelieve it or not, there are a few cultures in the world where back pain hardly exists.\nAnd it's quite different than American spines.\nMost Americans will at some point have a problem with their backs.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story isn\u2019t linked to any news release that we could find, and includes enough original reporting that we can be sure it wasn\u2019t based entirely on a release.", "answer": 1}, {"article": "In 2012, the Food and Drug Administration updated labeling on statins to include warnings about confusion and memory loss, elevated blood sugar leading to Type 2 diabetes, and muscle weakness.\nBut even with those risks, it\u2019s worthwhile, Gaziano\u2019s team found.\nIt would be, they report in the Journal of the American Medical Association.\nLimiting factors should be a patient's own preference about taking a daily pill, price and the risk of diabetes, they said.\nThere\u2019s an online tool that people or their doctors can use to calculate their risk of heart disease, which is based on age, sex, blood pressure and cholesterol levels.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not rely excessively on a news release.", "answer": 1}, {"article": "Worse, these same people tend to promote abstinence-only education, which has been shown conclusively to be the worst possible sex education; kids taught his way tend to have more pregnancies and more STIs than ones who are taught progressive, healthy sex ed.\nThe vaccines are not to blame here.\nThis, sadly, is expected; more than 178 million doses of Gardasil have been given worldwide, and given that huge number it\u2019s a statistical certainty that some young people will die not long after getting them.\nAnd, just like essentially every claim made by the anti-vaccination movement, these arguments are wrong.\nIt\u2019s very frustrating; mounds of data show these vaccinations are incredibly low-risk, but it only takes a little bit of doubt and fear to make vaccine rates drop.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There\u2019s enough context here that we can be sure the story does not rely on a news release.", "answer": 1}, {"article": "This measure of metabolic health is called \u201cinsulin sensitivity,\u201d and it is one of many metabolic functions that goes awry in people with obesity. In those who develop type 2 diabetes, sensitivity to insulin becomes so impaired that the body is tricked into believing less insulin is needed, and it pares back its production. The insulin-producing cells in the pancreas will often atrophy and die in response. As a person\u2019s insulin production declines, an external supply of insulin is needed to control blood sugar and deliver fuel to muscles and organs.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not seem to rely on a news release.", "answer": 1}, {"article": "Severely premature babies are more likely to live if they receive intensive-care treatments rather than palliative care to keep them comfortable, according to a U.S. government-funded study published Thursday.\n\nWhether babies born at the extreme edge of viability, generally considered to be 22, 23 or 24 weeks of gestation, should be aggressively medically treated is a controversial issue among pediatric experts. These infants often don\u2019t survive and, even if they do, many have substantial long-term health problems.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "We couldn\u2019t find any evidence online that the WSJ story was based on a press release, like this one from the University of Iowa. Plus, the inclusion of independent voices suggests original reporting.", "answer": 1}, {"article": "Some recreational swimming pools and homeowners with backyard pools have manual treadmills that are water-safe and can be plunked right in the water.\n\u201cI personally prescribe it for knee issues and low back issues.\u201d\n\nHydrotherapy uses a water-friendly treadmill that can be placed in a pool.\n\u201cAt waist height, it\u2019s at about 50 percent of body weight.\nThe water height can be adjusted to the patient\u2019s abilities.\n\u201cIt\u2019s a very pleasant way of achieving exactly what you\u2019re trying to do \u2013 allowing a cardio-respiratory response,\u201d Wolfe-Klein told CBS News.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not appear to be based on a news release.", "answer": 1}, {"article": "The average age for menopause is 51, with ovulation in most women ending sometime between age 40 and 60.\nWells said Tehrani\u2019s team appeared to have hit upon a \u201cfairly accurate algorithm\u201d for predicting menopause.\nExperts commenting on the work agreed it was promising, but said its findings would need to be confirmed in larger trials.\n\u201cIt will be important to let patients know that fertility will have declined greatly in the years preceding the final ovulation.\u201d\n\u201cWe developed a statistical model for estimating the age at menopause from a single measurement of AMH concentration,\u201d Tehrani explained in a report on the study.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There is no way to know if the story relied on a press release as the sole source of information.", "answer": 2}, {"article": "Atopic dermatitis is inherited and involves patches of highly itchy skin on any part of the body.\nTrial results were also reported on Tuesday in the New England Journal of Medicine, along with an editorial that said results of the study appeared \u201ccompelling\u201d at first glance and superior to those seen in previous studies of other asthma drugs.\nThe drug also met all its secondary goals, such as improving symptoms and lung function and reducing the need for standard drugs called beta agonists.\nSuch patients were deemed likely to benefit from treatment.\nBut she cautioned that longer trials are needed to fully assess the drug.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "This story does not rely on a press release.", "answer": 1}, {"article": "This slowly progressive enlargement of the prostate can make urination difficult or painful and send men trudging to the bathroom many times during the day and night.\nSurprisingly, his case is not unique.\u201d\n\nMany doctors are now urging men to become proactive earlier to prevent chronic problems in the future.\nNor does it lead to cancer.\nWatchful waiting, or monitoring symptoms while holding off on medical or surgical treatments, is a reasonable plan for these men, he added.\ncan lead to serious health problems for some.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not appear to be rely on a press release.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070520/28healthwatch.lede.htm was not found on this server.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "We can\u2019t be sure if the story relied solely or largely on a news release.\u00a0 Only one source is quoted.\u00a0 ", "answer": 2}, {"article": "In his study published in the International Journal of Radiation Oncology, Biology, Physics, he and his colleagues found, \"in circumstances where surgery may result in significant neurologic or organ dysfunction, patients can be treated definitively with radiation therapy alone.\nWhile the findings were written for health care professionals and very technical, Tracy was encouraged.\nThe San Francisco radiation oncologist not only shared Dr. Kabolizadeh's research paper, but also his contact information.\nEven with surgery, there was a high risk of recurrence.\nHe learned surgery is the most common treatment.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release doesn\u2019t employ sensational language. It makes no particular claims about the effectiveness of the relevant treatment option but notes only that it poses fewer risks than other radiation treatment options.", "answer": 1}, {"article": "Prostate cancer is the most common cancer among men.\nWhile the initial results were promising, they need to be replicated; HIFU also needs to be studied long-term and compared with other therapies.\n\u201cWhen you look at the current standard of care, there\u2019s a 1-in-3, or 1-in-2 chance of having the perfect outcome.\nFewer side effects would also lower other health care costs, he said.\nThe new study, designed as a proof-of-concept study, involved just 41 men.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story appears to be based on someone else\u2019s story \u2013 Bloomberg\u2019s.\nThe intent of this criterion is to promote independent vetting of claims.\nWe\u2019re not sure that happened any more with this approach than it would with copying from a news release.\nWe\u2019ll rule it Not Applicable because we certainly can\u2019t give this a Satisfactory score.", "answer": 2}, {"article": "For more information on ginkgo biloba, go to the U.S. National Center for Complementary and Alternative Medicine.\n\"Further, the subjects in the study were not monitored for certain cognitive parameters until several years after the trial began, creating difficulty in determining accurately whether they experienced a decline in cognition or not.\nThe report, published in the Dec. 23-30 issue of the Journal of the American Medical Association, supports the findings of earlier, smaller studies.\nThis age group is not typical of the age of both healthy people and those with mild cognitive impairment who use ginkgo for improving mental performance.\"\nNo measurable effect from ginkgo is seen on cognition, Schneider said.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Quotes from two of the sources \u2013 both defending ginkgo bliloba \u2013 were apparently taken from news releases.\u00a0 With the evidence stacking up against this product, why depend on canned responses to continue to breathe life into these product claims? ", "answer": 0}, {"article": "Randomized trials allow for the strongest inferences to be made about the true effect of an intervention such as a medication or a procedure.\nAbout 1 in 5 patients required additional medication to control their pain.\nWant to embed a link to this study in your story?\nWhy The Research Is Interesting: The United States is facing an opioid epidemic with almost 500,000 individuals dying from opioid overdoses since 2000.\nAuthors: Andrew K. Chang, M.D., M.S., of Albany Medical College, Albany, New York, and coauthors\n\nResults: After 2 hours pain was less in all participants, without any important difference in effect between the four groups.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "No unjustifiable language here.", "answer": 1}, {"article": "For dementia, which people with Type 2 diabetes have double the risk of developing compared with non-diabetics, metformin has been found in a number of studies to cut that risk substantially.\n\u201cThere are legitimate reasons to put patients on one drug rather than another.\nBut Price, a science and medical reporter in Oakland, Calif., doesn\u2019t have Type 2 diabetes.\nMoreover, the drug was being studied in clinical trials as a way to lower the risk of cancer, heart disease and dementia \u2014 not just for diabetics, but for everyone.\nBut such evidence often does not pan out in human studies.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There is enough original reporting here that we can be sure the story didn\u2019t rely excessively on a news release.", "answer": 1}, {"article": "Even today, in much of the developing world, people exercise through activities such as farming and fetching water that are necessary for survival.\nNothing in the data suggests that running more \u2014 farther, or faster \u2014 will do more to lower your risk of death.\nWe may tend to attribute the health of this group to their running habits.\nAt least in this article, I won\u2019t say anything about other kinds of exercise \u2014 no yoga or SoulCycle \u2014 though these have their own MET measures.\nEven if we dismiss the possibility that running harder is worse, it is probably useful to note that running harder or farther doesn\u2019t seem to be better.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The work does not appear to be based on a news release or other promotional materials.", "answer": 1}, {"article": "When Downing expressed concerns about the drug, she said the doctor blew her off: \"He said, 'What are you worried about?\nCandace's treatment, Downing said, involved a one-size-fits-all approach to mental health that sees medications as a magic pill.\nIf Caroline were going to get the same kind of mental health care as Candace, Downing wanted no part of it.\nThe treatment worked, she said, because \"getting all the stuff out of your head that you don't need there gives you more room for all the stuff you need to have in your head.\"\nThe therapy had an immediate and beneficial impact and turned Mathy Milling Downing, a skeptic about some kinds of mental health treatment, into a fan of mental health treatment done right.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Does not appear to rely on a press release.", "answer": 1}, {"article": "The first placebo-controlled study of two vaccines against the Ebola virus found they both successfully created a powerful antibody response for a year, suggesting they both could be tools to save lives in a future epidemic of the deadly disease.\n\nThe research, by doctors from the U.S. and Liberian governments and elsewhere, was published Wednesday in the New England Journal of Medicine. The study looked at 1,500 patients in Liberia, and took place amid and after the outbreak of Ebola in Liberia from 2014 into 2015.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "This story does not appear to rely on a news release.", "answer": 1}, {"article": "The Harvard Medical School affiliates share a clinical staff that delivers inpatient care at Boston Children's Hospital and most outpatient care at Dana-Farber Cancer Institute.\nEpizyme, a biopharmaceutical company based in Cambridge, MA, recently opened a pediatric trial of an Ezh2 inhibitor for children with rhabdoid and other tumors.\nThe new study grew out of efforts to discover whether different types of cancer are susceptible to Ezh2 inhibitors.\nJoining senior author Orkin, the study's lead author is Huafeng Xie, PhD, of Dana/Farber/Boston Children's.\nIt offers a promising approach to shortening the duration of therapy in order to achieve a cure.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The repeated use of the term \u201ccure\u201d \u2014 including in the headline \u2014 when only preliminary animal data is being presented \u2014 is unjustifiable.", "answer": 0}, {"article": "An inexpensive drug therapy far surpassed a conventional laser procedure in fixing a leading cause of blindness in babies born prematurely, according to a new study.\n\nThe results of the study, to be published this week in the New England Journal of Medicine, were so significant that the 15 hospitals participating in the research have stopped using lasers in favor of the drug, Avastin, which is injected into the eyes of the affected newborns. Avastin, made by Roche Holding AG's Genentech unit, is designed to be used for treating...", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "We didn\u2019t find signs that the article relied on a news release.", "answer": 1}, {"article": "Those on beta blockers had a substantial reduction in the formation of distant cancers, or metastases, and of local recurrence.\nAs in other retrospective studies, he said, more research is needed to verify the potential link.\nOther experts called the results interesting, but preliminary.\nPowe said he plans to do another study to validate the results.\nPowe is due to present the findings Friday at the annual European Breast Cancer Conference in Barcelona, Spain.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "This story does not rely largely on a news release. ", "answer": 1}, {"article": "Dr. Eric A. Klein, chairman of the Cleveland Clinic Glickman Urological and Kidney Institute, said that the study \"is confirmatory of a lot of other, smaller studies.\nPrevious studies have shown potential dangers related to androgen deprivation therapy in older men, Keating said.\nAlbertsen wrote an accompanying editorial in the journal.\nAnti-hormone therapy was developed to treat the pain and other problems of advanced prostate cancer, Albertsen said, and so it was generally used for only three to five years.\nDr. Peter Albertsen, a professor and chief of urology at the University of Connecticut Health Center, said that \"the point of this paper is to help physicians understand that long-term use of this therapy carries consequences.\"\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "\u00a0Does not appear to rely on a news release.", "answer": 1}, {"article": "They found that compared with the placebo, there was a 27% reduced risk of coronary heart disease, a 28% reduced risk of dying from coronary heart disease, and a 25% reduced risk of coronary \u201cevents\u201d such as a heart attack.\nResearchers from Imperial College London and the University of Glasgow found impressive results among those on statins, who were given the widely-prescribed type pravastatin.\n\u201cThis legitimises current guidelines which recommend treating this population with statins.\u201d\n\nRay said people with lower levels of cholesterol, around 4mmol/L, who otherwise appear healthy, should also be treated with statins.\nAll the men had very high levels of LDL, or \u201cbad\u201d cholesterol, (higher than 4.9mmol/L) but had no evidence of heart disease at the start of the study.\n\u201cThe role of cholesterol in causing heart disease has been disputed by some, but this paper provides yet more evidence of the link, and the benefits of statins to prevent heart disease.\u201d\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Quotes in this story directly match those from an Imperial College news release about the study, but there is no attribution given to the news release.", "answer": 0}, {"article": "\"This is a multi-channel implantable device,\" Peckham explains.\nIt was the lowest point of Annette's life; the woman who once trained dogs to assist the disabled would now be relying on one herself.\nBack then, she couldn't even wipe the tears from her eyes \u2014 and there were plenty of tears shed.\nThat's what happened to Annette in 2002 when a car accident left her paralyzed.\nAnd I do a little twitch with my muscle in here.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Although the story focused on just one patient at one institution, there is no way to know if the story relied on a press release as the sole source of information. ", "answer": 2}, {"article": "The tissue removed during surgery, which is usually discarded, was then analysed in the laboratory.\nThe researchers are continuing to investigate the use of this drug to treat Dupuytren's disease in a phase 2b trial called the RIDD trial, which is currently running in Oxford and Edinburgh.\nThey also found the drug to be safe and well tolerated.\nIn conjunction with Professor Sir Ravinder Maini, Sir Marc identified TNF as a therapeutic target in patients with rheumatoid arthritis.\n\"This type of work requires close collaboration between laboratory scientists, clinical trialists and clinician scientists over many years\".\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "Highlighting \u201cnew hope\u201d in the headline, and claiming \u201cthe results so far are very promising,\u201d are unjustified given this is a small, preliminary study showing changes in surrogate markers only two weeks after treatment in 28 subjects.", "answer": 0}, {"article": "Millions of Americans suffer from pet allergies that prevent them from enjoying the benefits of owning a dog or a cat.\nJoyce, who lives in the Bronx, New York, signed on for the year-long study that required six of the 12 volunteers to brush their teeth for two minutes using two pumps of the toothpaste in either the morning or night, and the other six to use drops under their tongue.\nShe consulted an allergist at Weill Cornell Medicine/New York-Presbyterian Hospital, where a clinical trial involving immunotherapy toothpaste was taking place.\nVolunteers using the toothpaste were also required to log their usage in a journal.\nAllerdent is not covered by insurance, meaning Joyce spends about $400 every three months but said the cost is worth it.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There is no indication that this story relied on a news release.\u00a0 However, the researcher\u2019s institution did produce a news release in 2014 that in some respects mirrors the Fox News story, relying on the anecdotes of one patient and comments from the inventor.", "answer": 1}, {"article": "Surgeons may also perform what\u2019s known as angioplasty, which uses a catheter to insert a tiny balloon and inflate it to open the valve; sometimes surgeons will also insert a stent, or tiny wire mesh cage, to keep the artery propped open.\n\u201cReplacing the aortic valve improves functional capacity,\u201d Kapadia, who wasn\u2019t involved in the study, said by email.\nParticipants were 82 years old, on average, and they were typically considered high-risk surgical patients due to either advanced age or other medical issues.\nResults of the current study reaffirm that a minimally-invasive procedure can be a viable option, even for elderly people who are high-risk surgical patients, said Dr. Samir Kapadia, a cardiovascular medicine researcher at the Cleveland Clinic in Ohio.\nOn average, they added almost 42 meters (138 feet) to their performance before surgery.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not appear to rely on a news release.", "answer": 1}, {"article": "Measuring blood levels of the recently discovered hormone irisin may improve diagnosis rates of teenagers with polycystic ovary syndrome, according to research presented today at the 55th Annual European Society for Paediatric Endocrinology Meeting\n\nMeasuring blood levels of the recently discovered hormone irisin may improve diagnosis rates of teenagers with polycystic ovary syndrome, according to research presented today at the 55th Annual European Society for Paediatric Endocrinology Meeting.\n\"If high irisin levels in teenagers with PCOS is established, this could lead to the development of treatments for PCOS.\n\"Teenagers who get an early diagnosis of PCOS can sooner start to deal with the physical and psychological symptoms caused by this lifelong condition,\" said lead researcher Dr Flora Bacopoulou.\nThe findings suggest that irisin could be a marker for PCOS allowing the condition to be diagnosed more easily.\nThe group will next focus on confirming their results and investigate the biological role of irisin in PCOS.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release uses language responsibly. It doesn\u2019t say that this will be a valuable diagnostic tool, but that it is a promising first step. As a result, we give it a satisfactory rating. However, the release ends by referring to irisin\u2019s potential as a drug target for future PCOS treatments. This is in a quote from a researcher, and is given in the context of \u201cfuture directions\u201d for the work, but it walks very close to the edge of \u201cunjustifiable language\u201d \u2014 primarily because, to the best of our knowledge, there is no research to support such a statement.", "answer": 1}, {"article": "\u2022 Swelling or thickening in part of the breast.\nIn some cases, women never develop any of these symptoms, Evers noted.\nAnd there are some lifestyle-related risk factors that can be controlled, such as hormone therapy after menopause, obesity, alcohol intake and physical inactivity, Evers said.\n\"With today's state-of-the-art treatment options and less extensive surgery, patients are experiencing better outcomes.\"\nThere are three tests often used to look for breast cancer, Evers said.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "This story appears to rely entirely on the news release.", "answer": 0}, {"article": "Breast cancer has a high rate of metastasis to bone, lung, liver, lymph nodes, and the brain.\n\u201cWe think this targeted approach holds great promise for earlier imaging of high-risk cancers in the clinic.\nTherefore, they expect it will be safe if ultimately developed for clinical use.\n\u201cOur imaging technology has the potential to differentiate aggressive tumors from low-risk tumors.\nThey will then pursue human trials with this approach.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "We\u2019ll give the story the benefit of the doubt here. The headline and lede paragraphs don\u2019t make clear that this is not about standard MRI, or that the work was done in mice. However, we\u2019ve already docked points for those infractions, and we think the language was otherwise responsible.", "answer": 1}, {"article": "Vitamin D, known as the \"sunshine vitamin,\" is produced by the body when it's exposed to sun.\nHowever, the study was small, and results from a larger trial aren't expected for several years, he added.\nThe findings also need to be replicated in a much larger number of patients, D'Amico said.\nBut Dr. Anthony D'Amico, chief of radiation oncology at Brigham and Women's Hospital in Boston, said that this study was too small to reach any definitive conclusion about the value of vitamin D in fighting prostate cancer.\nThe study results were scheduled for presentation Monday at the annual meeting of the American Chemical Society in Denver.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The article makes ample use of some of the language and information in the news release, but appears to have interviewed the researcher and an outside source to inform the story.", "answer": 1}, {"article": "In Canada, heart failure patients stay an average of almost 10 days for each hospital admission, accounting for 1.4 million hospital stays a year.\nSince it opened in 1997, the Centre has saved and improved the lives of cardiac and vascular patients from around the world.\nThe first Canadian patient implanted with the heart monitor will be among 25 patients within the Ted Rogers Centre for Heart Research at the Peter Munk Cardiac Centre to be fitted with the device over the next nine months.\n\u201cTraditionally we\u2019ve relied on a patient describing symptoms, and by then they may have already progressed to the point of hospitalization.\nThis is a big game-changer.\u201d\n\nFunded by the Ted Rogers Centre for Heart Research, the device called CardioMEMS\u2122 HF System was successfully implanted by interventional cardiologists at the Peter Munk Cardiac Centre in March 2017.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The leading quote includes terms such as \u201cepidemic\u201d and \u201cbig game-changer.\u201d First of all, heart failure is not an infectious disease, and only one person has undergone this therapy at the Cardiac Centre.\nThe headline and leading sentence also talks about the device being a \u201cfirst\u201d in Canada without any mention of previous implantation procedures in other countries.\nThese word choices could be misleading and raise red flags in our eyes. Therefore, we give the news release a Not Satisfactory rating.", "answer": 0}, {"article": "\u2022 LPCN 1021 was well tolerated and had a favorable safety profile in the long-term management of hypogonadal patients\n\u2022 No hepatic, cardiac or drug-related serious adverse events were reported\n\u2022 The most common drug-related adverse events for LPCN 1021 and T gel 1.62 percent were acne (2.9 percent vs. 2.9 percent, respectively), headache (0.5 percent vs. 3.8 percent, respectively), weight increase (2.4 percent vs. 0 percent, respectively), hematocrit increase (1.9 percent vs. 0 percent, respectively), liver enzyme level increase (1.4 percent vs. 0 percent, respectively), fatigue (0.5 percent vs. 1.9 percent, respectively), and hypertension (0.5 percent vs. 1.9 percent, respectively)\n\u2022 Lipid parameters (i.e., cholesterol, LDL, HDL, and TG) were comparable between treatment groups at Week 52\n\u2022 Androgenic parameters including hematocrit, hemoglobin, platelet, prothrombin, and prostate-specific antigen (PSA) showed no significant differences in change from baseline to end of study between treatments\n\n\"Based on the results of this study, we might be closer than ever to having an oral form of therapy to treat the millions of men with hypogonadism,\" said Dr. K\u00f6hler.\nFollowing a 13-week efficacy phase, men continued to receive their assigned treatment for up to 52 weeks.\nThe research will be highlighted by study authors during a special press conference to be moderated by Tobias S. K\u00f6hler, MD, MPH, FACS, AUA spokesperson and associate professor of Surgery at Southern Illinois University on May 8, 2016 at 7:30 a.m. PT in the San Diego Convention Center.\nIt is often administered as a gel, patch, injection or implant (pellet).\n\"Making sure an oral treatment is safe and effective for men and for the children and partners at risk for inadvertent testosterone transference is the top priority, and what we've found so far has shown we're on the right track.\"\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release does not rely on sensationalist language.", "answer": 1}, {"article": "The U.S. National Cancer Institute has more about colon and rectal cancer.\n\"The results of our study help to further clarify the importance of different durations of NSAID use over time for the risk for dying from colorectal cancer,\" Coghill noted in the news release.\nThe findings were slated for presentation on Sunday at the AACR International Conference on Frontiers in Cancer Prevention Research, in Boston.\nStudy participants were enrolled in the Women's Health Initiative, which \"represents a large and well-characterized cohort [group] of postmenopausal women, and the medication data collected in this cohort made it possible for us to investigate multiple types, durations and strengths of NSAID use,\" Coghill explained.\nIn the study, researchers examined the use of aspirin and non-aspirin NSAIDs among more than 160,000 postmenopausal women in relation to deaths from colorectal cancer.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story clearly was based on a press release by the American Association for Cancer Research. Similar language and the same quotations were used. In fact, the press release was a bit more thorough than the actual HealthDay article. There was not any evidence of original reporting.", "answer": 0}, {"article": "Not since 1998, when the FDA approved the PSA test for early detection of prostate cancer, had new technology been created in early cancer detection until the stool DNA test.\nUp until June 1, LabCorp of America had a product on the market.\n\"Clearly by itself, it is not reaching other people,\" said Markowitz, who sits on the medical advisory board of the National Colorectal Cancer Research Alliance.\nIt will be geared toward use in the privacy of one's home.\nBut it's a huge step forward, especially for those who are skittish about a trip to the doctor.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story borrows a phrase from a company press release, saying the noninvasive stool test can be used \u201cin the privacy of one\u2019s home,\u201d but it does not appear to be overly reliant on a press release.", "answer": 1}, {"article": "One in six American adults lives with high cholesterol, and millions have trouble getting it under control, according to the Centers for Disease Control and Prevention.\nIn an editorial published along with the study, experts note that although the results are promising, more long-term research is needed to make definitive conclusions about the drug.\nNow, researchers believe a a new type of experimental drug may help change that.\nThe results, published in the Annals of Internal Medicine, also show that the drugs have a significant effect on reducing heart attacks and overall mortality.\nResearchers analyzed 24 randomized control trials to assess the efficacy and safety of the new drugs, called PCSK9 antibodies, in adults with high cholesterol levels.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Since the story quotes an independent expert, we can be sure it didn\u2019t rely entirely on a news release.", "answer": 1}, {"article": "Migraines are characterised by an intense, throbbing headache, sensitivity to light and noise, nausea, vomiting, low energy, and visual disturbances.\nLead investigator Prof Peter Goadsby, from King\u2019s College hospital, London, said: \u201cStrive \u2026 represents an incredibly important step forward for migraine understanding and migraine treatment.\u201d\n\nThe findings, reported in the New England Journal of Medicine, clearly showed that blocking the CGRP pathway could reduce the impact of migraine, he said.\n\u201cThis is probably the first example of a migraine preventing drug that was rationally designed, rather than serendipitously found,\u201d he added.\n\u201cPlacebo responses [in migraine studies] are quite high and I think that is partly due to the subjective nature of pain and because of the strong psychological effects that being treated have on that experience of pain and those symptoms,\u201d he said, adding that injections generally result in an even stronger placebo effect than tablets.\n\u201cAn option that can prevent migraine and that is well tolerated is therefore sorely needed, and we hope that this marks the start of real change in how this condition is treated and perceived.\u201d \n\n\n\n\u201cBroadly speaking I think this is a very interesting study and I think it is a good step forward for the field and I think it is a good day for migraine sufferers,\u201d said professor Zameel Cader, Director of the Oxford Headache Centre who was not involved in the research, pointing out that the results were on a par with currently available therapies for migraine.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story quotes the principal investigator, Peter Goadsby, but doesn\u2019t note the source of those quotes: A press release by King\u2019s College London, where Goadsby is a professor. So when The Guardian reports that Goadsby \u201csaid\u201d such and such, it implies that he said it directly to someone at\u00a0The Guardian. \u00a0But he did not. \u00a0In fact, we don\u2019t even know if Goadsby \u201csaid\u201d those things or wrote them, in a note to the PR people. \u00a0It\u2019s not a best practice to grab quotes from a PR news release while failing to attribute the source.", "answer": 0}, {"article": "March 7, 2011 -- Traditional Chinese acupuncture may be useful in reducing the severity of hot flashes and other symptoms of menopause, a new study suggests.\nA five-point scale was used to measure the severity of hot flashes, vaginal dryness, urinary symptoms, mood swings, and other symptoms in the postmenopausal women.\nTwenty-seven women received traditional Chinese acupuncture twice a week for 10 sessions from an experienced and licensed acupuncturist.\nHalf of them received traditional acupuncture treatment.\nThose in the comparison group were treated with shams needles at the same acupuncture points.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It does appear that the story relied solely on a news release.\u00a0 Some of the language is nearly identical.\nFor example:\nNews release:\n\u201cThey suggest that the explanation for the reduced severity of hot flushes might be that acupuncture boosts the production of endorphins, which may stabilise the body\u2019s temperature controls.\nThe authors caution that their study was small and that they did not monitor how long symptom relief lasted, but they suggest that traditional Chinese acupuncture could be an alternative for those women unable or unwilling to use hormone replacement therapy to ease troublesome menopausal symptoms\u201d\nStory:\n\u201cThe researchers say reduced severity of hot flashes may have occurred because acupuncture boosts production of endorphins, which may stabilize the temperature control system of the body.\nBecause the study was small, the researchers say more investigation is needed but that their results seem promising, suggesting traditional Chinese acupuncture could be an alternative for women who are unable or unwilling to use hormone replacement therapy in the pursuit of relief of menopausal symptoms.\u201d\n\u00a0", "answer": 0}, {"article": "PD-1 or PD-L1 inhibitors work by blocking a mechanism of tumors that allows them to evade detection by cancer-fighting cells.\nEsophageal cancer is the seventh most commonly diagnosed cancer in the world, the company said.\nKeytruda, when compared to chemotherapy, enabled certain patients with esophageal cancer to live longer, helping the drug meet the main goal of the late-stage study, Merck said.\nMerck said trial results would be presented at an upcoming medical meeting.\n\u201cThis marks the sixth tumor type where Keytruda has demonstrated a survival benefit, and represents the first time an anti-PD-1 therapy has achieved overall survival for this patient population,\u201d said Roy Baynes, chief medical officer of Merck Research Laboratories.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Everything in the story appears to be based on a Merck announcement.", "answer": 0}, {"article": "\"It's just like physical exercise -- when we are approaching the new year we will buy a pass for the gym and go fervently in January and then slack off,\" Willis said.\nMental skills acquired earlier in life persist well into old age, he said.\nRather, as is the case with physical exercise, strengthening the mind appeared to slow decline.\nExperts said the federally funded study is a call to action for anyone who has ever worried about developing Alzheimer's, dementia and similar disorders.\nSomeone who hates to play games, she said, should find something else that stretches the mind.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Does not appear to rely on a press release.", "answer": 1}, {"article": "Red and purple fruits owe their colors to...\nMuch of the popularity is the work of a California-based company, Pom Wonderful.\nAlthough it's a challenge to eat the raw fruit without getting a mouthful of seeds and astringent pith, pomegranates are everywhere now in the form of juice, concentrates and extracts, all heavily promoted for better health.\nBut is it especially healthful?\nThe juice is a beautiful wine-red color and tastes delicious.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "We can\u2019t be sure if the story relied solely or largely on a news release. Then again, no sources are cited except a California company, so it\u2019s not clear what sources were relied on. ", "answer": 2}, {"article": "But if we tailor treatments to the individual biology of the tumor and characteristics of the patient, we'll get the best results,\" Wolf says.\nAs part of a Specialized Program of Research Excellence, or SPORE, grant, the team was already maintaining long-term follow-up data on patients.\nThe non-responders who were immediately referred for surgery had better outcomes too.\nAfter a decade of using this approach, researchers are reporting \"exceptional\" survival rates nearing 80 percent, even for the most advanced patients.\n\"This adds ammunition to the idea that we need to pick individual therapies more carefully.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "We give this a satisfactory rating, but want to make two notes \u2014 one on something we particularly like to see, one on something that we don\u2019t. First, kudos to the headline on the news release. It clearly conveys the relevance of the finding without overselling it. The headline doesn\u2019t tell us that the technique picks the best course of treatment; instead, the headline tells us that the new technique helps patients and doctors make a decision about what course of action is best. That\u2019s good to see. Lower down, the story refers to a survival rate as \u201cunheard of.\u201d What does that mean? People say and hear all kinds of things. Are they referring to clinical trial results? Longitudinal study findings? Hearsay? When possible, we discourage the use of this sort of vague language; it offers readers little insight, and does more to confuse a subject than to clarify it. The language in this instance was not sufficiently hyperbolic to warrant a \u201cnot satisfactory\u201d rating, but it\u2019s close.", "answer": 1}, {"article": "Professor Tim Newton from the Dental Institute at King's College London and lead author of the study said: \"People with dental phobia are most commonly given sedation to allow them to become relaxed enough for a short period of time to have their dental treatment performed.\nNearly all patients (94%) reported a knock-on effect from problems with their teeth, mouth or gums on their daily living and quality of life.\nCognitive behavioural therapy could help many people with a dental phobia overcome their fear of visiting the dentist and enable them to receive dental treatment without the need to be sedated, according to a new study by King's College London.\nThe average number of CBT appointments required before a patient received dental treatment without sedation was five.\nCBT provides a way of reducing the need for sedation in people with a phobia, but there will still be those who need sedation because they require urgent dental treatment or they are having particularly invasive treatments.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release is cautious in its use of language, and is very careful to acknowledge the limitations of CBT in addressing dental phobia. For example, the first sentence of the release states that CBT \u201ccould help many people with dental phobia.\u201d It does not say that CBT will help or that it could help all people with dental phobia.", "answer": 1}, {"article": "Although surgeons can also take X-rays during the posterior procedure, it is much more difficult, and they wait until patients are in the recovery room, where, Bollinger says, \u201cthere\u2019s not much that can be done.\u201d He explains that while the body \u201ctolerates an imperfect alignment pretty well, if a new hip gets dislocated, it\u2019s often because it\u2019s not in perfectly.\u201d\n\nRobert Saunders, a nurse at Alta Bates Summit Medical Center in Berkeley, Calif., sees about 200 hip replacement patients a year.\nMany patients aren\u2019t aware of the option.\nAccording to those who use this anterior technique, the benefits are substantial.\nUnger says his was relatively short \u2014 about 20 cases.\nUnger says that most surgeons have used the posterior approach for years, have fine results, and see no need to switch.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not rely on a press release.", "answer": 1}, {"article": "AsthmaNet is a nationwide clinical research network created by the NHLBI in 2009.\nAsthmaNet studies are currently being conducted in 14 states.\nThe study, funded by the National Heart, Lung, and Blood Institute's (NHLBI) asthma network (AsthmaNet), appears in the August 18, 2016, issue of the New England Journal of Medicine.\nNone of the study investigators, children, or caregivers knew which study drug each child was receiving.\nAbout 4,900 undergraduate and 5,900 graduate students comprise our student body.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The news release from University Hospitals Case Medical Center does not use unjustifiable, sensational language.", "answer": 1}, {"article": "UCSF Benioff Children's Hospital Oakland (formerly Children's Hospital & Research Center Oakland) is a premier, not-for-profit medical center for children in Northern California, and is the only hospital in the East Bay 100% devoted to pediatrics.\nThe CHORI-bar is intended as a non-traditional means to positively impact the obesity epidemic by initiating a healthier metabolism without requiring sudden drastic behavioral changes.\nDevelopment of the CHORI-bar has also been guided by Dr. Mark Shigenaga's insights into the importance of a healthy gut supported by optimal nutrition for disease prevention.\nImproved metabolism resulting from eating the bar is also associated with a number of reports of feeling better (though this observation has not yet been formally tested), which the CHORI team predicts will help people transition to improved lifestyle habits.\nBruce Ames and Mark K. Shigenaga at Children's Hospital Oakland Research Institute (CHORI), was shown in clinical trials to improve metabolism in overweight/obese (OW/OB) otherwise healthy adults in ways that are consistent with reduced risk of type 2 diabetes and cardiovascular disease.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release makes unjustified claims of \u201cbroad health improvement\u201d that aren\u2019t backed up by evidence \u00a0The very idea that the bar may be effective for\u00a0individuals who make no other changes in their diet or physical activity levels is highly questionable. The release crosses over into salesmanship in several instances such as this one: \u201cThe power of nutrient-rich, properly formulated food-based supplements, such as the CHORI-bar, to move dysregulated metabolism in a healthy direction may help reverse obesity-associated conditions, and thereby reduce the risk of future chronic diseases.\u201d", "answer": 0}, {"article": "Diseases like Alzheimer\u2019s start years, even decades, before the first symptoms of memory loss shows up.\nMORE: New Test May Predict Alzheimer\u2019s 10 Years Before Diagnosis\n\nWhile his test is a possible solution to that problem, he acknowledges that the results need be repeated before it\u2019s recommended on a wide scale to physicians across the country.\nFor now, even if doctors identify patients around age 65 who might be at higher risk of developing cognitive impairment, there isn\u2019t much they can do to interrupt the process.\nThat would look for known genetic factors linked to Alzheimer\u2019s, including the presence of certain versions of the ApoE gene.\n\u201cBut what\u2019s nice about it is that it\u2019s a nice non-cognitive, motor factor so it\u2019s looking at another aspect of brain function.\u201d\n\nMORE: This Alzheimer\u2019s Breakthrough Could Be a Game Changer\n\nPetersen suggests that every physician should get this information on their patients at age 65; that way, they can have a baseline against which to compare any changes as their patients age.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The quotes used in the story are different from those found in this\u00a0news release so we can be sure the story includes an interview with the study author.", "answer": 1}, {"article": "The use in spine surgery of bone-growth proteins like Medtronic Inc.\u2019s product Infuse has led to widespread nationwide increases in hospital charges ranging from 11% to 41% above conventional surgical costs, researchers found.\n\nThe researchers studied the results of a broad U.S. sample of 328,000 spine surgeries from 2002 through 2006. They report their findings this week in JAMA, the Journal of the American Medical Association.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Given the history and the potential conflict of interest question raised in the story, it is safe to assume that it did not rely on a news release. ", "answer": 1}, {"article": "Women taking oxybutynin also reported improvement in work, social activities, leisure activities, sleep and overall quality of life.\nDrugs in this class -- called anticholinergics -- have been linked with mental decline, he said.\nThese are vital issues, Police said.\nThe research was scheduled to be presented Friday at the San Antonio Breast Cancer Symposium in Texas.\nThe patient said endocrine therapy had caused hot flashes so severe that she could not sleep.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The article included original comments not found in the news release.", "answer": 1}, {"article": "Achillion\u2019s ongoing mid-stage study tests its NS5A inhibitor, ACH-3102, with Sovaldi in previously untreated genotype 1 hepatitis C patients over six and eight weeks of therapy.\nMonday\u2019s data shows Achillion\u2019s NS5A inhibitor, ACH-3102, looks best-in-class, which could make up for its nuke, ACH-3422, being perhaps less effective than Sovaldi, analysts said.\nThe all-Achillion regimen could hit the U.S. market by 2020 in a conservative scenario, Deutsche Bank\u2019s Alethia Young estimated.\nShe expects the treatment to cost about $35,000 per patient per year, assuming a 55 percent discount.\nAchillion\u2019s shares rose as much as 19 percent to $12.85 on Monday on investor\u2019s hopes that an all-Achillion combination could be as effective as Gilead\u2019s and AbbVie Inc\u2019s current therapies.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story takes a quote from this Achillion news release, but it alerts readers to the fact that the language came from \u201ca statement.\u201d Since no independent perspectives are offered, we can\u2019t really be sure to what extent this story relied on the news release, so we\u2019ll rate it Not Applicable.", "answer": 2}, {"article": "Guidelines from the American Cancer Society and other organizations recommend that women age 30 and older are screened using Pap smears and tests for the human papillomavirus, or HPV.\nIn that case, women would need more invasive tests to rule out disease, Roland said, and risk \u201cundue harm\u201d from those procedures.\n\u201cOften a provider just does the HPV test\u201d without telling the patient.\n\u201cA woman should say, \u2018What screening tests are you doing on me?\u2019\u201d\n\nAnd if doctors want women to come back again next year, women should ask them why, Saraiya said.\nThat\u2019s because HPV \u2014 which causes changes in the cervix that can lead to cancer \u2014 may take a decade to progress to that point.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It\u2019s clear the story didn\u2019t rely on a news release.", "answer": 1}, {"article": "\"To address inconsistencies in prior studies on vitamin D and to investigate associations in population subgroups, we analyzed participant-level data, collected before colorectal cancer diagnosis, from 17 prospective cohorts and used standardized criteria across the studies,\" said Stephanie Smith-Warner, PhD, an epidemiologist at the Harvard T.H.\nThe study appears online in the Journal of the National Cancer Institute.\nHowever, risk did not continue to decline at the highest concentrations.\nThis study strengthens the evidence, previously considered inconclusive, for a protective relationship.\nThese associations persisted even after adjusting for known colorectal cancer risk factors.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "There are no instances of unjustified language.", "answer": 1}, {"article": "NEW YORK (Reuters Health) - Doctors can use a patient\u2019s abdominal CT scans to also check for signs of the bone-weakening disease osteoporosis, according to a new study.\nThat may spare the patients from additional testing and additional costs.\nDr. Sumit Majumdar, who wrote an editorial accompanying the new study, said a lower threshold for bone density would catch most cases of osteoporosis and limit \u201cincidentaloporosis\u201d - incorrect osteoporosis diagnoses \u201cdiscovered\u201d while doctors were looking for something else.\nDespite DXA scans being safe and cost effective, Pickhardt and his colleagues say the test is underused.\n\u201cWhat we found is that there is pretty good correlation,\u201d said the study\u2019s lead author Dr. Perry Pickhardt, professor of radiology at the University of Wisconsin School of Medicine and Public Health in Madison.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It\u2019s clear that the story did not rely on a news release.", "answer": 1}, {"article": "The review also found that zinc cut the number of days that kids missed school because of being sick and reduced the use of antibiotics by cold sufferers.\n\u201cThe evidence from the recent trials does support the use of zinc lozenges in treatment of common cold,\u201d says study researcher Meenu Singh, MD, a pediatric pulmonologist at the Post Graduate Institute of Medical Research in Chandigarh, India.\nIt updates a 1999 Cochrane review that found no strong evidence to recommend zinc as a help for colds.\nIt also appeared to prevent colds in people who used it over the course of about five months.\n\u201cWe really don\u2019t have interventions for colds that work.\u201d\n\nThe review of 15 studies with 1,360 participants was published by the Cochrane group, an international collaboration of researchers that reviews evidence behind therapeutic interventions.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not rely on a news release.", "answer": 1}, {"article": "As many as 10 percent of children suffer from hay fever, nearly 12 percent have skin allergies, and 5 percent have food allergies, most commonly peanuts, dairy, and shellfish, according to the 2014 National Health Interview Survey.\nInterest in Circassia had been sky-high \u2014 the small biotech\u2019s market value had shot up to $1 billion earlier this year on speculation that its drug would prove effective.\n\u201cThat hypothetically decreases the risk for adverse events.\u201d\n\nFor all the research on allergies, none of the drugs in the pipeline is a sure thing.\nThe company\u2019s stock plummeted on that news this past June.\nBut they can be deadly in the modern era.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The article was certainly not based on a single news release.", "answer": 1}, {"article": "And if I can be saved, so can other people.\u201d\n\nThe study results were unveiled Thursday in advance of a major cancer conference next month.\nBut she added that an ongoing study in the United Kingdom involving 200,000 women should more definitively determine the test's value.\nBut none proved as accurate as CA-125 after a Harvard scientist developed a mathematical model combining trends in test results and a patient's age.\nThere is no such screening tool currently in use.\nAmong the study participants was Liz Stegall, who enrolled at the request of the family of Linda Nelson Taylor, a friend who died of ovarian cancer that wasn't diagnosed until it was advanced.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Because the story quotes an independent expert and a patient, the reader can assume the story did not rely on a press release as the sole source of information.", "answer": 1}, {"article": "Drs.\nThis study and others are providing evidence for changes in obstetric practice that could help safely reduce c-section rates.\nThis study suggests that IV fluids could help women maintain hydration at appropriate levels, reduce the likelihood of c-section, and decrease length of labor,\" says Dr. Berghella.\n\"The results are compelling and strongly argue for a change in practice,\" says Vincenzo Berghella, M.D., the Director of Maternal Fetal Medicine and Professor in the Department of Obstetrics and Gynecology at the Sidney Kimmel Medical College at Thomas Jefferson University.\nWith the data pooled, the researchers could see a clear difference in outcomes for women in the two groups.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "Both the text wording and a quote from the lead researcher suggest that the results of this meta-analysis are applicable to all women in labor, a conclusion that is not supported by the original research report. Additionally, the source declares, early in the release, that the results of the analysis \u201care compelling and strongly argue for a change in practice.\u201d Again, the limitations of the meta-analysis do not seem to warrant such prescriptive\u00a0language.", "answer": 0}, {"article": "After the cap is placed on the patient's head, it is attached to a vacuum pump that sucks the air out of the cap, jamming the tiny grounds together to form a rigid layer that conforms closely to the shape of the patient's head.\nIn this case, the cap proved to have 66 percent lower error rates than the headband.\nIt was the way the reflective markers were attached to the patient's head that was at fault.\nOn the strength of these results, Vanderbilt University has applied for a patent on the design and the technology is available for licensing.\nThey discovered it wasn't the hardware or the software in the guidance system that was causing the problem.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The news release maintains a restrained approach, with the exceptions of the headline and the lead. \u201cHow six cups of ground coffee can improve nose, throat surgery\u201d is vague and misleading, since there\u2019s no proven benefit yet. And it doesn\u2019t strike us as accurate to describe this as \u201cplopping six cups of coffee grounds on the heads of patients just before they are wheeled into the operating room to have nose or throat surgery.\u201d", "answer": 0}, {"article": "\"Our idea was to find a way to do a quick examination that would allow, during a boxing or American football match for example, to determine whether the athlete can return to the field or if his condition requires hospitalization.\nYet 90% of these patients will be able to return home safely, as no trauma has been detected.\nThis discovery, described in PLOS ONE, will not only relieve emergency departments, free patients from often long waits, but also save on costly medical examinations.\nToday, the injured patients have to go to the emergency rooms of hospitals equipped with a CT Scan, an expensive examination that sends X-rays to the brain to detect the presence or absence of brain trauma.\nHis team has developed a rapid diagnostic test (POCT) called TBIcheck, inspired by the principle of pregnancy testing: by placing a single drop of blood on the well of a small 5cm plastic case, the patient knows within 10 minutes whether there is a risk of mild trauma, namely whether or not his H-FABP level is higher than 2.5 nanograms per millilitre of blood.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The headline \u2014 \u201cA brain injury diagnosed with a single drop of blood\u201d \u2014 was among several examples of language in this news release that exaggerated the benefits of this test. Another was that patients will have \u201cNo more doubts!\u201d about whether they might have a concussion. It is not clear that this test will improve outcomes in any way.", "answer": 0}, {"article": "In the current trial, the women who were randomly selected to receive talazoparib had a higher response rate to treatment than women who received standard chemotherapy: 63 percent versus 27 percent, the researchers found.\nSimilar drugs have already been used to treat advanced, BRCA-mutated ovarian cancer, according to the agency.\nThis targeted form of treatment takes advantage of a weakness in the BRCA gene to further cripple the cancer cell's ability to repair itself, grow and spread, said Weiss, who was not involved with the study.\nThe drug does have side effects.\nThe trial was funded by drug maker Pfizer, and the results were published Aug. 15 in the New England Journal of Medicine.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not appear to rely on a news release.", "answer": 1}, {"article": "The median age at diagnosis for cancer of the prostate is 66.\n\"Despite these figures, we found that a structured yoga intervention in the form of twice-weekly classes is feasible for patients during a six- to nine-week course of outpatient radiotherapy for prostate cancer,\" said Vapiwala.\nThe new, first-of-its-kind study, led by Neha Vapiwala, MD, an associate professor in the department of Radiation Oncology at PSOM and Penn's Abramson Cancer Center, found that general quality of life and measurements of side effects often experienced by prostate cancer patients--including fatigue, sexual health, and urinary incontinence--were stable throughout a course of outpatient radiation therapy among the men participating in an intensive yoga program.\nCurrently, the team is randomizing prostate cancer patients to participation vs. no participation in this structured yoga program in order to further characterize the potential benefits of yoga in this population.\nThe possible explanation for the benefits of yoga seen in the study stems from physiologic data demonstrating its ability to help reduce cancer- as well as treatment- related fatigue and to strengthen pelvic floor muscles and increase blood flow.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The lead sentence quotes researchers at the University of Pennsylvania stating that men with prostate cancer who are undergoing radiation therapy \u201ccan benefit from yoga.\u201d\u00a0 In her closing quote lead researcher Neha Vapiwala, MD, associate professor at the University states, \u201cWe offer several ways to enhance quality of life, minimize or reduce side effects of cancer and cancer treatment, and promote healing and recovery.\u201d\nBut nowhere in the news release are we given more than anecdotal evidence to support those assertions.\nThere was no data supporting the claim that more men than expected participated. Where did that idea come from? Given that the population was men with cancer one would expect them to be more\u00a0 open to alternative therapies.", "answer": 0}, {"article": "Deep brain stimulation involves implanting electrodes in the brain, then connecting them to a pulse generator placed under the skin of the chest.\nWhat's needed, said Fargo, is research that compares deep brain stimulation against a placebo device.\nThat patient was LaVonne Moore, 85, of Delaware, Ohio.\nThere is no larger trial in the works yet, according to Scharre.\nAll three patients were in the earlier stages of Alzheimer's and were on standard medications.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story draws from sources other than a Ohio State Wexner Medical Center news release.", "answer": 1}, {"article": "A popular new type of prenatal test intended to find genetic flaws in a fetus can in rare cases also reveal previously undiagnosed cancer in the mother.\n\nThe unexpected finding emerged in a study involving eight women who initially had abnormal results from the prenatal blood test, but for whom a subsequent assessment showed their babies were normal. When the mothers\u2019 DNA was reanalyzed, researchers said, the anomalies were linked to cancer in each of the women.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There was a JAMA release on the study, but the story also appears to be solidly based on a presentation at a scientific society meeting and the JAMA article and accompanying editorial.\n\u00a0", "answer": 1}, {"article": "He uses an electric mobility scooter for long distances, but he can still walk.\nThe Vertin brothers are not among them; the drug shouldn\u2019t help them at all.\nBut the family\u2019s struggles with DMD were just beginning.\nOther, secondary measurements did seem to have good statistics.\nThe agency still has nearly two more weeks to make a decision.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story clearly does not rely on a news release.", "answer": 1}, {"article": ".\nSubmit to The FASEB Journal by visiting http://fasebj.\nBy activating the bitter taste receptors in the uterus, the bitter substances relaxed the contracted uterine muscle tissue more completely than the current drugs used to prevent preterm labor in humans.\n\"The bitter taste receptors that we have found on uterine muscle could be one more piece of the puzzle to understand the onset of labor, both at term and preterm, and develop new therapeutics for preterm labor.\"\nThey then exposed the tissue to bitter substances.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release doesn\u2019t rely on sensational language. As noted above under disease mongering,we found some examples of exaggeration in the release.", "answer": 1}, {"article": "When the heart beats, it generates a waveform, and with a healthy heart and vasculature there are fewer and smaller waves.\nTwo thousand IUs decreased stiffness by 2 percent in that timeframe.\nThe test essentially measures the speed at which the blood is moving, and in this case, fast is not good, Raed says.\nParticipants taking 4,000 international units - more than six times the daily 600 IUs the Institute of Medicine currently recommends for most adults and children - received the most benefit, says Dr. Anas Raed, research resident in the MCG Department of Medicine and the study's first author.\n\"It significantly and rapidly reduced stiffness,\" Raed says.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The tone of the release is carefully measured throughout, with the writer repeatedly using language like \u201cmight\u201d and \u201cappears to be.\u201d", "answer": 1}, {"article": "The Ache: The bathroom scale shows how much you\u2019ve gained or lost in pounds, but gives no information about whether the change is fat or muscle.\n\nThe Claim: A whole-body scan, called Dual-Energy X-ray Absorptiometry, or DXA for short, gives a detailed snapshot of your body composition, including how your body weight breaks down into fat, bone and lean tissue.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There is enough original reporting here that we can be sure the story wasn\u2019t based entirely on a news release.", "answer": 1}, {"article": "More than 5 million Americans have Alzheimer\u2019s, and this number is expected to grow as the population ages.\nThe study is a very long way from showing that.\nAnd, McCracken says, the company is working to figure out just what it is in the plasma that might affect aging and disease.\nResearchers trying to answer the question say they found the treatments are at least safe.\nBut that doesn\u2019t mean there really was an effect.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "This story does not appear to have relied on a news release. In this cast, that\u2019s unfortunate since a news release produced by Stanford University is more cautious and comprehensive in its detail than is this NBC story.\n\u00a0", "answer": 1}, {"article": "For more on childhood obesity, visit the U.S. Centers for Disease Control and Prevention.\nWhether those children were in another preschool program wasn't stated.\nHealth benefits, including weight loss, seem to be a byproduct of the program, said Dr. David Katz, director of the Yale University Prevention Research Center.\nThe daily routine might translate into less TV time and more regular sleep schedules, she said.\n\"The essence of this study is the holistic nature of social, psychological and physical health.\"\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Since the story includes comments from an independent expert, we can be sure it didn\u2019t rely solely on a news release.", "answer": 1}, {"article": "Relatively few women at high risk of breast cancer take tamoxifen, and some patient advocates question whether they should, saying many women are exposed to side effects for each case of cancer prevented.\nThe new information presented here and published in the medical journal included a detailed analysis of the side effects of the drugs and the results of a survey of about 10 percent of the 19,747 women in the trial concerning their physical and mental well-being.\nAs for the data on vaginal and vulvar cancer prevention, they came from combining data from three trials used to test the ability of the vaccine, Gardasil, made by Merck & Company, to prevent cervical cancer.\nThe editorial in the journal said the new data \"still may not be enough to convince primary care physicians to be more aggressive than they have been to date in breast cancer chemoprevention.\"\nThe new data are not likely to settle the debate about which drug is better.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story cites information from both the editorial that accompanied these studies as well as the researcher who presented the results at a professional meeting. It might have been helpful to note that neither the authors of the editorial nor the presenter appear to have any financial relationship with either drug manufacturer; this information was available in the published articles. ", "answer": 1}, {"article": "Tim Barham, the vice president of HBB, the maker of Lazy Cakes, said, \u201cWe look at the brownie as a supplement.\u201d\n\nNews reports have classified Lazy Cakes as dietary supplements, but last month, Douglas Karas, an F.D.A.\nBut she added, \u201cI don\u2019t want to go on the record saying this drug \u2018can\u2019 cause respiratory issues, that should be a \u2018may.\u2019 \u201d\n\nLazy Cakes appear harmless, even amusing, with swirly purple packaging; Kush Cakes have a tie-dye-printed wrapper.\nFor me, it\u2019s to get a good night\u2019s sleep.\u201d\n\nYet the products, intended for adults only, are being marketed as a novel way to relax in a stressed-out, wired world.\nOf melatonin, Dr. Seres warned, \u201cIf you take it while you\u2019re driving a car, you will find yourself in a ditch.\u201d\n\nMaybe.\nDr. Lewy dismissed the idea that harm might lurk in a melatonin-laced brownie.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It\u2019s clear that the story did NOT\u00a0rely on a news release.", "answer": 1}, {"article": "In 2008, Medicare paid for 480,000 injections of Avastin to treat macular degeneration and 337,000 injections of Lucentis, according to a study led by Dr. Philip Rosenfeld of the University of Miami.\nBut there has never been a definitive trial to compare the two drugs.\nStill, doctors will be looking closely at details of the data.\nSafety of the two drugs will also be closely watched.\nThe result was largely expected.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story doesn\u2019t appear to rely on a news release.\n", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070723/23healytip.htm was not found on this server.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story did not include any quotes or comments from anyone either associated with the research or a recognized expert in the field so we can\u2019t be sure if the story relied solely or largely on a news release.", "answer": 2}, {"article": "CHICAGO (Reuters) - Children in rural Nepal whose mothers were given iron and folic acid supplements during pregnancy were smarter, more organized and had better fine motor skills than children whose mothers did not get them, U.S. researchers said on Tuesday.\n\u201cIt had an impact across a range of function, including intellectual function, executive function and fine motor function,\u201d factors that could affect a child\u2019s later academic success, Christian said.\nThe study was funded by the National Institutes of Health and the Bill & Melinda Gates Foundation.\n\u201cThese results speak to a large swath of people residing in that part of the world.\n\u201cWhat we showed is prenatal iron and folic acid supplementation had a significant impact on the offspring\u2019s intellectual level and motor ability and ability during school age, which was a very exciting finding,\u201d she said.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not rely on a news release.", "answer": 1}, {"article": ",org *2014 Journal Citations Report published by Thomson Reuters \u00a92015\n\nElsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress.\nThere are over two million cases a year in the U.S. and the lifetime risk of developing a BCC before the age of 85 years is one in five people.\n\"The main advantages of noninvasive treatments are good cosmetic outcome, preservation of surrounding tissue, and potential for home application of either creams,\" explained lead investigator Marieke Roozeboom of the Department of Dermatology, Maastricht University Medical Center in the Netherlands.\n\"When choosing a treatment for an individual patient with a superficial BCC, other factors like age, compliance, and patient preferences should always be taken into account.\nA three-year randomized controlled clinical trial has found that two topical creams are effective in most primary, low-risk superficial BCC, comparing favorably with photodynamic therapy (PDT), as reported by investigators in the Journal of Investigative Dermatology.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "No unsupported claims were made.", "answer": 1}, {"article": "The Ache: In the digital age, many people spend hours daily bent over computers, phones and tablets\u2014our necks craned forward. Some scientists say this unnatural position can lead to pain, headaches and other symptoms, sometimes collectively called \u201ctext neck.\u201d\n\nThe Claim: Technology itself comes to the rescue. An Android app called the Text Neck Indicator measures the angle of your phone and lets you know when you\u2019re holding it in a favorable viewing position. And a new wearable device, Alex, monitors the angle of your neck...", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not appear to rely on a news release.", "answer": 1}, {"article": "Tiotropium bromide (Spiriva)) belongs to a class of drugs called anticholinergics, which work by enlarging the airways to allow for easier breathing.\nThese drugs carry a note on their labels warning of the possibility of severe adverse events, including death, he noted.\nThat's important, Peters said, because there have been some safety concerns raised about long-acting beta agonists.\nIn addition, Spiriva's safety profile among asthmatics still needs to be studied, he said.\nHowever, the study authors and an outside expert stressed that these are early findings and much longer, larger clinical trials are needed.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "We haven\u2019t found evidence that the article relies on a news release.", "answer": 1}, {"article": "RA Nash et al.\nDr. Nash served as principal investigator of the HALT-MS study.\nThe experimental treatment aims to suppress active disease and prevent further disability by removing disease-causing cells and resetting the immune system.\n\u201cAlthough further evaluation of the benefits and risks of HDIT/HCT is needed, these five-year results suggest the promise of this treatment for inducing long-term, sustained remissions of poor-prognosis relapsing-remitting MS,\u201d said Richard Nash, M.D., of Colorado Blood Cancer Institute and Presbyterian-St. Luke\u2019s Hospital.\nThree participants died during the study; none of the deaths were related to the study treatment.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The tone of this news release is restrained, with no sensational language.", "answer": 1}, {"article": "Drinking cow\u2019s milk produced at night may be a treatment for anxiety and insomnia, suggests an animal study in the Journal of Medicinal Food.\n\nA glass of milk at bedtime has long been touted as a sleep aid. But the study found that milk collected at night, or night milk, had enhanced sedative effects in mice compared with milk produced during the day. Night milk significantly decreased the rodents\u2019 physical activity, balance and coordination and increased sleep time compared with day milk, the research showed.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "We couldn\u2019t find a news release to compare with the story. But since no independent sources are quoted, we can\u2019t be sure the story didn\u2019t rely on a news release. We\u2019ll rate this Not Applicable.", "answer": 2}, {"article": ".\nStill, pridopidine does not get at the underlying cause of Huntington's disease, Di Rocco said.\nThe results of the phase 3 clinical trial, conducted by Spanish researchers led by Dr. Justo Garcia de Yebenes, of the department of neurology, Hospital Ramon y Cajal in Madrid, appear in the Nov. 7 online edition of The Lancet Neurology.\nAnother expert agreed that new treatment options for patients are sorely needed.\nMore than 70 percent of the patients taking the higher dose of the drug showed a significant benefit, according to the researchers.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The same quotation in the news release is used in the HealthDay story, suggesting that the article was somewhat based off the news release. However, there is some evidence of original reporting, with the inclusion of Dr. Alessandro Di Rocco\u2019s comments.", "answer": 1}, {"article": "In Manhattan some raw-milk drinkers hire a mule to bring the white stuff to an agreed-upon location in...\nNow that's trickier.\nNo?\nAnd they consider themselves lucky.\nGot milk?\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Given multiple sources, there is no evidence the story relied solely or largely on a news release.\u00a0 ", "answer": 1}, {"article": "A team led by Dr. Philip Dennis of the National Cancer Institute, part of the National Institutes of Health, studied metformin in mice exposed to a potent, cancer-causing agent in tobacco called nicotine-derived nitrosamine ketone or NNK.\n\u201cThis important laboratory study, together with prior laboratory and epidemiology research, suggests that metformin may be useful in cancer prevention and treatment,\u201d said Dr. Michael Pollak of McGill University in Montreal, who wrote a review on metformin research in the same journal.\nThe findings were so strong the team now wants to test it in smokers to see if it can keep then from developing tumors.\n\u201cAlthough smoking cessation is the most important step for current smokers, over half of lung cancer cases are diagnosed in former smokers, raising the importance of identifying those at highest risk and identifying effective preventive treatments,\u201d Dennis, whose findings were published in the journal Cancer Prevention Research, said in a statement.\nThey said metformin prevented lung tumor growth in mice exposed to a cancer-causing agent found in tobacco smoke, and because it is already widely used in people, it may be worth further study.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Not applicable because we can\u2019t be sure of the extent to which the story may have been influenced by a news release. \u00a0There\u2019s no evidence of any independent interviewing, since quotes seem to come from published statements or from journal review comments. ", "answer": 2}, {"article": "Whether you've been relatively inactive or fairly athletic, age is the enemy of one of the most important sets of muscles in the body: the group of four known as the rotator cuff that surround the ball of the shoulder joint.\n\nAbout 54% of adults older than 60 have a completely or partially torn rotator cuff, compared with just 4% of those between 40 and 60. But tears are most frequently caused by degeneration of the tendon due to age, rather than injury from sports or trauma. Studies show that tears can be managed without...", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not rely on a news release.", "answer": 1}, {"article": ".\nThe new study, published in The European Journal of Internal Medicine, found cannabis therapy is safe and efficacious for elderly patients who are seeking to address cancer symptoms, Parkinson's disease, post-traumatic stress disorder, ulcerative colitis, Crohn's disease, multiple sclerosis, and other medical issues.\n\"After monitoring patients 65 and older for six months, we found medical cannabis treatment significantly relieves pain and improves quality of life for seniors with minimal side effects reported.\"\nWhile the researchers state their findings to date indicate cannabis may decrease dependence on prescription medicines, including opioids, more evidence-based data from this special, aging population is imperative.\nMore than 70 percent of patients surveyed reported moderate to significant improvement in their condition.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The title of the release, \u201cMedical cannabis significantly safer for elderly with chronic pain than opioids,\u201d goes far beyond what the study found. It implies this was a comparative study.\nIt\u2019s overreaching to imply\u00a0that cannabis is \u201csafe and efficacious\u201d in treating nearly a dozen conditions based solely on the self-reporting of a small number of subjects, and in an observational study that can not establish cause and effect.", "answer": 0}, {"article": "The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices.\nThe drug is approved for use with a companion diagnostic, the LeukoStrat CDx FLT3 Mutation Assay, which is used to detect the FLT3 mutation in patients with AML.\nThe FDA granted this application Priority Review, Fast Track (for the mastocytosis indication) and Breakthrough Therapy (for the AML indication) designations.\nWomen who are pregnant or breastfeeding should not take Rydapt because it may cause harm to a developing fetus or a newborn baby.\nThe FDA granted the approval of Rydapt to Novartis Pharmaceuticals Corporation.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "No unjustifiable language here.", "answer": 1}, {"article": "More than one million athletes experience a concussion each year in the United States.\nEach of the concussed athletes had their brain blood flow measured with the advanced ultrasound headset within an average of six days after the injury.\n\"This important work provides insight into a tool that may yet prove useful in the recognition and management of concussion,\" said Jeffrey Kutcher, MD, FAAN, with the The Sports Neurology Clinic in Brighton, Michigan.\nThe study was supported by the National Institutes of Health and the National Science Foundation.\n\"This research suggests that this advanced form of ultrasound may provide a more accurate diagnosis of concussion,\" said Hamilton.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "Although the text does not shy away from demonstrating\u00a0that the\u00a0technology under study does a better job of detecting changes in blood flow among concussed athletes than do other diagnostic strategies, it also offers cautionary comments that make clear the device is still very much in the testing phase.", "answer": 1}, {"article": "He whips up a homemade concoction using frozen elderberries, blueberries and honey.\nBut Kevin Brennan says, for his family, the natural alternative seems to be working.\nThe University of Maryland Medical Center says European elder, also called black elder, is the variety most often used for medicinal purposes.\nBefore you start popping elderberries, beware: eating them raw can make you sick.\nThat would be similar to prescription antiviral medications like Tamiflu or Relenza, which have been proven effective in much larger studies and approved by the FDA to shorten the duration of the flu.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story appears to be based on some original reporting.", "answer": 1}, {"article": "Nov. 5, 2012 (Los Angeles) -- An IV infusion of \"good\" HDL cholesterol seems to rapidly remove cholesterol out of plaque-clogged arteries following a heart attack, a small, early study suggests.\nThe goal of the new treatment is to reduce the high risk of a second heart attack in people who have had a heart attack.\nStandard heart attack medications, such as aspirin and anti-clotting drugs, prevent clotting but don\u2019t eliminate an underlying factor: cholesterol that has built up on artery walls, he says.\nGille is head of clinical and translational science strategy at CSL Limited (which funded the study) in Parkville, Australia.\nHDL removes cholesterol from artery walls, but current HDL-boosting drugs, such as niacin and fibrates, take years to work, according to Gille.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It does not appear that the story relied solely or largely on a news release.", "answer": 1}, {"article": "Kidney stones are small, hard mineral deposits that form inside the kidneys, affecting up to 12 percent of men and seven percent of women.\nThis finding could lead to the first advance in the treatment of calcium oxalate stones in 30 years.\nThe head-to-head studies of CA and HCA determined that while both compounds inhibit the growth of calcium oxalate crystals, HCA was more potent and displayed unique qualities that are advantageous for the development of new therapies.\nThe work offers the first evidence that the compound hydroxycitrate (HCA) is an effective inhibitor of calcium oxalate crystal growth that, under certain conditions, is actually able to dissolve these crystals.\nThe most effective inhibitors reported in the literature simply stop the crystal from growing.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release generally sticks to careful language about the potential benefits of hydroxycitrate, clearly noting that further studies are needed. However, the release would have been better if the cautionary notes about the need to do human safety and effective trials had been near the top, instead of buried at the bottom of the release.", "answer": 1}, {"article": "Neurologists estimate that about 38% of people who suffer from migraines stand to benefit with such a regimen, and studies suggest that as many as half of migraines can be prevented with drugs, according to Dr. Stephen D. Silberstein, a neurologist at the Jefferson Headache Center at Thomas Jefferson University in Philadelphia.\nYou can read the new guidelines here, or check out the patient-friendly summary here.\nIt can cause throbbing pain in the head.\nIf you had a history of suffering from migraines and could prevent the debilitating headaches by swallowing a few pills, you\u2019d do it \u2013 wouldn\u2019t you?\nEach headache may last from four hours to two days.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "We can\u2019t be sure of the extent to which the story relied on a news release.\u00a0 We do know:\n\u00a0", "answer": 2}, {"article": "[Watch how the body\u2019s \u2018serial killers\u2019 stalk and attack cancer cells]\n\n\"This is a first in class agent, a brand new therapy,\" Harrington said.\nBut this is the first time a modified virus has been successful in carrying out that treatment.\nWhen the latest trial was started, Harrington explained, there was no standard of treatment for melanoma -- so it's compared to a treatment that no one expected to outpace T-VEC.\nBut cancer cells aren't as savvy, and T-VEC has its run of them.\nSo in addition to the destructive power of the T-VEC cells themselves, the therapy summons the immune system right to where it's needed -- the tumor.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "While the news release from the Institute of Cancer in London features quotes from the same researcher, the quotes in the story seem different enough that we can rule out excessive reliance on a news release.", "answer": 1}, {"article": "Lowering A1C levels helps reduce the risk of long-term complications from diabetes such as eye, kidney and heart disease.\nBergenstal said patients who are not achieving their goals with multiple daily injections should consider using a pump and sensor.\n\u201cWhat we\u2019ve been able to show is that by combining this technology, you can lower the A1C, which reduces your risk of complications, and you can do it safely without increasing your rate of hypoglycemia,\u201d said study author Dr. Richard Bergenstal, executive director of the International Diabetes Center at Park Nicollet Health Services in Minneapolis.\n* Average reductions of 0.8 pct seen in levels of A1C\n\nCHICAGO, June 29 (Reuters) - Medtronic Inc\u2019s (MDT.N) insulin pump and monitoring device controlled blood glucose levels better than multiple daily injections in patients with Type 1 diabetes, according to a large post-market study.\nAdult and pediatric patients using the pump and continuous glucose monitoring device saw reductions in levels of A1C, a commonly used measure of blood sugar, that were four times greater than those who received regular insulin injections in the study of 485 patients ranging from age 7 to 70.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>\n\n\n\n \nNot applicable because we can\u2019t be sure of the extent to which the story relied on a news release. The quote used in this story does not appear in the news releases available for review. However, the story fails to include any information beyond that provided by Medtronic in its news release: http://wwwp.medtronic.com/Newsroom/NewsReleaseDetails.do?itemId=1277813641618\u2329=en_US\n", "answer": 2}, {"article": "(That\u2019s a high dose; a 3 oz.\nThe effects remained strong even after the researchers accounted for the fact that all of the people were taking standard heart disease treatment drugs, including cholesterol-lowering statins and blood pressure medications.\nThese are questions Kwong and others hope to answer with more studies.\nHow much omega-3 is needed to start remodeling the heart in a beneficial way?\n\u201cBut I do think it\u2019s logical that our results hold promise, and may reduce bad outcomes in patients after a heart attack.\u201d\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The article does not appear to be based on a news release.", "answer": 1}, {"article": "Chemotherapy deals heavy damage to tumors \u2014 but often, the cancer cells are able to regroup and repair themselves.\nSo far, there\u2019s just extremely early data, but it looks promising.\nThe hope is that they\u2019ll keep cancer at bay once it\u2019s been attacked by chemo.\nIts results built upon exciting data it released in June \u2014 showing that its drug can increase the window of time in which a woman\u2019s cancer doesn\u2019t get worse.\nShe\u2019s launching a larger trial for further study.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There is no indication\u00a0that this story relied on a news release.", "answer": 1}, {"article": "\u2022 Pregnant women who were hospitalized with severe cases of flu illness were half as likely to have been vaccinated as women with non-severe illness.\nA related editorial commentary by Alan T. N. Tita, MD, PhD, and William W. Andrews, PhD, MD, of the University of Alabama at Birmingham, accompanies the new study in The Journal of Infectious Diseases.\nSixty-three of these patients, or about 7 percent, had severe illness.\nThe findings also underscore the importance of flu vaccination for this risk group.\nFor an embargoed copy of the study and the commentary, please contact Emily Zaideman (312-558-1770, ezaideman@pcipr.com).\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release doesn\u2019t go overboard with unjustifiable language.", "answer": 1}, {"article": "A new study has an intriguing finding: Advanced cancer patients who received early palliative care in conjunction with standard care for their disease not only reported better quality of life, but lived a few months longer than patients who received only standard care.\n\nThe research, published in the New England Journal of Medicine, included 151 patients diagnosed with metastatic non-small-cell lung cancer who were randomly assigned to one of those treatment plans. At 12 weeks, 86% of those who were still alive filled out assessments \u2026", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Since the story includes an interview with an expert not affiliated with the study, we can be sure that it didn\u2019t rely solely on a news release.", "answer": 1}, {"article": "The GI tract is also home to the intestinal microbiome, a complex population of roughly 100 trillion microorganisms (more than ten times the number of cells that make up the human body) that interacts with the mucosal lining of the GI tract.\nAnd a new study from Baltimore's Sheppard Pratt Health System, conducted by a research team led by Faith Dickerson, finds that a probiotic supplement may reduce inflammation of the gut, which is known to exacerbate bipolar disorder.\nA group of patients recently hospitalized for mania participated in a 6-month study to track the effects of probiotic treatment on both their mood and the status of their immune system.\nWith this in mind, researchers developed a probiotic supplement aimed at reducing inflammation caused by microbial imbalances in the gut.\nThis connection, named the \"gut-brain axis\" (GBA), allows for crosstalk between the endocrine, immune, and autonomic nervous systems.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "Along with the unsubstantiated headline suggesting \u201cmillions\u201d of people who suffer with bipolar disease could be helped by probiotics, the release employs the pseudoscientific term \u201cgut-brain axis\u201d to suggest there are known connections between good and bad bacteria, microbial balance, and psychiatric mood disorders.\nBut without data, much of the language used throughout the news release is unjustified.", "answer": 0}, {"article": "For more on dietary supplements, visit the Office of Dietary Supplements of the U.S. National Institutes of Health.\n\"While this of course needs to be confirmed with follow-up, I do think the subject is absolutely worthy of further exploration,\" Vinson added.\nThe study was broken into three six-week sections.\n\"This was indeed a small study,\" acknowledged corresponding study author Joe Vinson, a professor of chemistry at the University of Scranton, in Pennsylvania, but he noted that prior research has been conducted in both France and Japan.\nThey don't even necessarily have to be tested for purity.\"\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The study included enough independent commentary to assure us that it wasn\u2019t based entirely on a press release.", "answer": 1}, {"article": "WASHINGTON -- The Food and Drug Administration on Wednesday approved ImClone Systems Inc. and Bristol-Myers Squibb Co.'s Erbitux as a treatment for head and neck cancer, the agency said Wednesday.\n\nThe drug, which is designed to block proteins involved with cancer growth, was first approved in 2004 as a colon cancer treatment.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Identical phrases appear in the story and in the FDA\u2019s news release. The lack of independent sources also suggests that the author has relied on the press release as the only information source.", "answer": 0}, {"article": "In 2016, breast cancer accounted for 29 percent of all new cancers identified in the United States and was responsible for 14 percent of all cancer-related deaths.\nAABGU, which is headquartered in Manhattan, has nine regional offices throughout the United States.\nAs Ben-Gurion University of the Negev looks ahead to turning 50 in 2020, AABGU imagines a future that goes beyond the walls of academia.\n\"Our new approach utilizing urine and exhaled breath samples, analyzed with inexpensive, commercially available processes, is non-invasive, accessible and may be easily implemented in a variety of settings.\"\nIt is a future where Ben-Gurion U. invents a new world and inspires a vision for a stronger Israel and its next generation of leaders.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release doesn\u2019t employ sensational, unjustifiable language.", "answer": 1}, {"article": "MS can cause many symptoms, including blurred vision, loss of balance, poor coordination, slurred speech, tremors, numbness, extreme fatigue, problems with memory and concentration, paralysis and blindness.\nThose deaths are a major concern, one neurologist said, because MS is not in itself life-threatening.\nThose deaths were related to the transplants, Saccardi said.\nMedications can slow the progression of MS and help patients manage symptoms, but there's no cure.\nA trial that compares stem cell transplants with other therapies to see whether stem cell transplants can become a treatment for patients who have progressive MS is about to start, added Racke, who co-authored an editorial that accompanied the study.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story appears to go beyond any news releases we were able to find regarding the paper.", "answer": 1}, {"article": "Dr. Len Lichtenfeld, deputy chief medical officer of the American Cancer Society, said it's clear that \"some women with metastatic breast cancer have benefited from Avastin, but others not only have not benefited, they've been harmed.\nBased on the new data, an FDA advisory panel voted 12-1 to reverse the accelerated approval in July.\nThe announcement does not affect Avastin's status as an approved therapy for lung cancer, kidney cancer, colorectal cancer and brain cancer.\nAlong with the initial approval, the FDA required Genentech, Avastin's maker, to complete larger studies.\nThe results of those studies were a bitter pill for patients thriving on Avastin and researchers excited by the promise of the early data.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It doesn\u2019t appear to have relied solely or largely on the FDA\u00a0release.", "answer": 1}, {"article": "This is sent to the USB stick, which shows the result on a computer or electronic device.\nThe device, created by scientists at Imperial College London and the privately-held U.S. firm DNA Electronics, uses a drop of blood to detect HIV, then creates an electrical signal that can be read by a computer, laptop or handheld device.\nIt could be particularly useful in remote settings to help HIV patients manage their treatment more effectively, since current tests to detect virus levels take at least three days and involve sending a blood sample to a laboratory.\nSome 36 million people worldwide are infected with the human deficiency virus (HIV) that causes AIDS, and the majority of them live in sub-Saharan Africa.\nCurrent AIDS drugs, called anti-retrovirals, reduce virus levels in a patients blood to near zero.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Quotes were copy and pasted directly from the ICL press release, and we didn\u2019t detect any signs of original reporting. \u00a0\u00a0\nFrom the news release:\n\u201cHowever, monitoring viral load is crucial to the success of HIV treatment. At the moment, testing often requires costly and complex equipment that can take a couple of days to produce a result. We have taken the job done by this equipment, which is the size of a large photocopier, and shrunk it down to a USB chip.\u201d\nAnd the Reuters news story:\n\u201cMonitoring viral load is crucial to the success of HIV treatment. At the moment, testing often requires costly and complex equipment that can take a couple of days to produce a result,\u201d said Graham Cooke, who co-led the research from the Imperial\u2019s department of medicine. \u201cWe have taken the job done by this equipment, which is the size of a large photocopier, and shrunk it down to a USB chip.\u201d", "answer": 0}, {"article": "The National Fibromyalgia Association estimates that about 10 million Americans, mostly women, have fibromyalgia, an unexplained condition characterized by chronic pain and fatigue.\nXyrem also helped reduce fatigue, stiffness, and other symptoms, she tells WebMD.\nAlso, small, preliminary studies suggested the drug can reduce pain and fatigue in people with fibromyalgia.\nThe new study was presented at the annual meeting of the American Pain Society.\nXyrem, which is approved by the FDA for the treatment of narcolepsy, corrects the same disturbed sleep patterns that studies have shown are common in fibromyalgia patients, Jones says.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "While we don\u2019t know what sources the article used, we didn\u2019t see a press release out there that it cribbed from.\u00a0", "answer": 1}, {"article": "CHICAGO (Reuters) - Two new drugs using very different scientific approaches can extend survival among patients with the deadliest form of skin cancer, offering the first new hope for real progress in many years.\nShe and others expect vemurafenib to be approved this year.\nThe five-year survival rate for the aggressive cancer is just 15 percent.\n\u201cWe don\u2019t know what dacarbazine did to the ipilimumab, but we do know even in the presence of dacarbazine, ipilimumab still produced a durable response and extended survival.\u201d\n\nDoctors said taken together the new studies offer new options for patients.\n\u201cThat is a drug that can take a while to work, so if the person has time I would rather give him essentially two shots on goal rather than one.\u201d\n\nFor advanced patients who need a quick response, he would use vemurafenib first.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It\u2019s clear that the story did not rely on a news release.", "answer": 1}, {"article": "Ishdori A, Capps O, Murano PS.\nThe executive summary \"Science and Policy: Adopting a Fruitful Vegetable Encounter for Our Children,\" is available online at http://advances.\nThe USPB was established in 1971 by a group of potato growers to promote the benefits of eating potatoes.\nThe supplement is the outcome of a November 2014 USDA/ARS Children's Nutrition Research Center at Baylor College of Medicine roundtable on vegetable consumption in children.\nThe forum was supported by the Alliance for Potato Research and Education, a not-for-profit organization dedicated to expanding and translating scientific research into evidence-based policy and education initiatives that recognize the role of all forms of the potato--a nutritious vegetable--in promoting health for all age groups.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The headline \u2013 and use of \u201cbest hope\u201d \u2014 is unjustified, as far as we can tell.", "answer": 0}, {"article": "\"Anything we can do to get those rates up has the potential to save lives.\nThe study was slated for presentation Monday at the American College of Gastroenterology's annual meeting in Washington, D.C. Because this study was presented at a medical meeting, the data and conclusions should be viewed as preliminary until published in a peer-reviewed journal.\nThe study authors suggested that the findings could help reduce the number of people affected by invasive colorectal cancer -- the third most common cancer diagnosed in men and women in the United States, according to background information in the news release.\nDetection rates for the first doctor were about 67 percent while listening to music and 30 percent with no music.\nThis was up from a baseline detection rate of 21 percent before the study began.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story clearly was based on a press release by the American College of Gastroenterology. Similar language and the same quotations were used. There was not any evidence of original reporting.", "answer": 0}, {"article": "It is also not available for pregnant women, people with heart conditions or very high blood pressure, patients with kidney disease or clotting disorders, patients on blood thinners, patients with a history of strokes or brain tumors and people with substance abuse issues.\nThe paper outlines the results of an international clinical trial, led by Jeff Elias, MD, of the University of Virginia Health System, that evaluated the scalpel-free approach called focused ultrasound for the treatment of essential tremor (ET), a condition that afflicts an estimated 10 million Americans.\nThe essential tremor research has been supported by InSightec, the Focused Ultrasound Foundation and the BIRD (US-Israel Binational Industry Research and Development) Foundation.\n\u201cThe degree of tremor control was very good overall in the study, but the most important aspects were the significant gains in disabilities and quality of life \u2013 that\u2019s what patients really care about,\u201d Elias said.\nNot only did the researchers determine that the procedure was safe and effective, they found that it offered a lasting benefit, reducing shaking for trial participants throughout the 12-month study period.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release steps over the line several times in its use of hyperbole, beginning with the headline, \u201cScalpel-free surgery proves safe, effective for treating essential tremor,\u201d that ignores the high proportion of adverse effects reported in the study and the limited time \u2014 12 months \u2014 that the study covered.\u00a0 Saying a procedure is safe without long-term studies is an exaggeration.\u00a0 Further on, subheads refers to it as a \u201cpioneering tremor trial\u201d and \u201cgroundbreaking research.\u201d", "answer": 0}, {"article": "Autopsies show that most men will develop prostate cancer in their lifetimes but often die of something else.\nThe research, published in today's Journal of the American Medical Association, is the first to directly examine what has become conventional wisdom: that many older men need not treat early prostate cancer because it tends to grow so slowly that they will probably die of something else first.\nWong acknowledged that the study's design had limitations, making it important that the findings be confirmed by additional research.\nOther experts expressed skepticism, saying the study's design may have missed another explanation for the lower death rate among men who were treated: They were probably healthier in ways that doctors can tell only by examining them, not by looking at their medical records, which is what the study's authors did.\nBut she said she and her colleagues analyzed the data carefully to account for factors that could have influenced the findings, such as the subjects' ages and whether they had other health problems.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Because the story relied on a number of independent sources, it is safe to assume it did not rely solely or largely on a news release. ", "answer": 1}, {"article": "MayoClinic: Find out more about melanoma\n\nOne study presented at the American Society of Clinical Oncology's (ASCO) conference on Sunday focused on the experimental drug vemurafenib.\nNearly 90% benefited from this new targeted drug, Schuchter said.\nIt doesn't target a specific part of the cell.\nYervoy takes a while to work, and some patients may not have that time, study author Chapman said.\nThis is very unusual in the world of drug development, he said.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It\u2019s clear the story did not rely on a news release.", "answer": 1}, {"article": "WASHINGTON -- A U.S. Food and Drug Administration panel of outside medical experts backed a Novartis AG drug, Exelon, for treatment of dementia in patients with Parkinson's disease.\n\nExelon is currently on the market to treat mild to moderate Alzheimer's disease. The FDA said it wasn't sure whether dementia associated with Parkinson's was much different than dementia associated with Alzheimer's. Dementia is a condition that typically first presents itself as memory loss greater than what would be expected as part of the normal...", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There is no obvious evidence the story relies on a press release. ", "answer": 1}, {"article": "Honey is not only cheap and readily available, it's also generally safer than cough medicine, which can have side effects or be administered in the wrong dose.\n\"(Honey) is a cheap and effective treatment,\" said Dr. Ian Paul, lead investigator for the study.\nHoney also beat out no treatment at all.\nOne local pediatrician said she wouldn't discourage parents from trying honey with their children, but more studies are needed to draw solid conclusions.\n\"I would be reluctant to routinely recommend to all parents that they give honey, because in some rare cases children can have reactions to honey.\"\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There is no way to know if the story relied on a press release as the sole source of information.", "answer": 2}, {"article": "The Centers for Disease Control and Prevention recognizes many diabetes prevention lifestyle change programs, delivered both in-person and online, including Vida, which bills itself as a \"health transformation team\" that is data and tech-driven.\nAnd he says the convenience of having the program delivered on a smartphone was key, too.\nAnd he says he's pleased with the results of the pilot study of Omada's program.\nSo he says that was a disappointment.\nNot every Omada Health participant makes the progress they're aiming for.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The article does not appear to rely on a news release.", "answer": 1}, {"article": "Hot flashes typically begin in the year or so before menopause and tend to abate in the years afterward.\nResearchers knew who was receiving sham treatment, but the women, who completed questionnaires detailing the extent of their hot flashes, did not.\nTo prove it is effective in reducing hot flashes, the Mayo team needed to demonstrate that it was superior to sham, or placebo, treatment.\nThat doesn't surprise Adriane Fugh-Berman, associate professor in the complementary medicine program at Georgetown University School of Medicine.\nVincent's group recruited 103 women between the ages of 45 and 59 who reported that they had at least five hot flashes per day and were not using any other treatments for them.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There is no evidence that this story relied on a news release. ", "answer": 1}, {"article": "In a similar study published in the journal Pediatrics in 2004, researchers recruited 100 children with upper respiratory tract infections who had been coughing for an average of over three days.\nUltimately, the honey produced the greatest improvements when it came to better sleep and reduced cough frequency and severity.\nIn this occasional series, the New York Times \u201cReally?\u201d columnist, Anahad O\u2019Connor, explores the claims and the science behind alternative remedies that you may want to consider for your family medicine cabinet.\nAlthough children in all three groups experienced a reduction in coughing, those who received the flavored water fared the best.\nThe thinking is that sweet substances of any kind help soothe the back of the throat and break up mucus in the airways.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not rely on any news releases.", "answer": 1}, {"article": "Nicotine itself does not cause the body to create antibodies as part of an immunological response, the way disease-causing viruses and bacteria do.\nThomas E. Rathjen, a spokesman for Nabi Biopharmaceuticals, said the results of the study should be available sometime next year.\nIf the vaccine helps smokers quit, Dr. Reus said, a central question will be whether booster shots could help prevent relapse.\nBecause the compound is too big to cross the blood-brain barrier, the vaccine is expected to diminish or eliminate the pleasure associated with puffing a cigarette.\nThe total number of subjects in the trial is expected to be about 300.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It appears that the story does not rely solely on a press release for information used in the story. ", "answer": 1}, {"article": "Because this important step is out of the way in advance, it completely changes the patient\u2019s day of surgery experience.\u201d\n\nRadar can target abnormality within 1 mm, sparing more healthy tissue\n\nUnlike mastectomy, which treats breast cancer by removing an entire breast, lumpectomy surgery \u2014 also known as breast-conserving surgery \u2014 is used to remove only the tumor and a small amount of tissue surrounding the tumor.\nThe SAVI SCOUT Radar Localization System helps to decrease the time a woman is in the operating room, increase the success rates of lesion removal and reduce the amount of healthy breast tissue that is removed during the procedure.\nIn addition to enhancing the patient\u2019s surgical experience, the more precise localization of the surgical site enable surgeons to plan the procedure better.\n\u201cUltimately, this wireless technology has the potential to reduce surgical delays, and more importantly will benefit patients by increasing comfort and satisfaction during a stressful time,\u201d Madrigrano said.\n\u201cWhen the marker was inserted near the lump, it was similar to a biopsy.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release doesn\u2019t rely on sensational language. The benefits claims are carefully worded and provide a positive view of the technology. Statements such as: \u201cUltimately, this wireless technology has the potential to reduce surgical delays, and more importantly will benefit patients by increasing comfort and satisfaction during a stressful time,\u201d are technically correct when viewed as a potential. However, the release is consistent in its suggestion that the technology is a clear advance over existing methods, without offering any comparisons or data.", "answer": 1}, {"article": "Pancreatic cancers, also uncommon, were numerically fewer with Januvia, 9 versus 14.\nThere were 228 such hospitalizations for Januvia and 229 in the placebo group, according to data also published in the New England Journal of Medicine.\nThe detailed results also showed no increase in hospitalization for heart failure, which had been a particular concern with DPP-4 inhibitors, the class to which Januvia belongs.\n\u201cWe can be reassured we can use this drug for glucose lowering without affecting the already high cardiovascular risk in people with type 2 diabetes,\u201d said Professor Rury Holman, the study\u2019s lead investigator, who presented the data at the American Diabetes Association meeting in Boston.\nDeath from any cause occurred in 7.5 percent of Januvia patients versus 7.3 percent for placebo.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not overly rely on a news release. It appears that one of the study authors was interviewed.", "answer": 1}, {"article": "However, relatively little research has been conducted into ketamine's antidepressant effects in adolescents.\nHowever, they note that the study was limited by its small sample size, so future research will be needed to confirm these results.\nJames Stone, a clinical senior lecturer from the Institute of Psychiatry, Psychology and Neuroscience at King's College London, who was not involved in the study, told Newsweek that there is \"a lot of potential for the use of ketamine as a second or third line antidepressant where other treatments have failed.\"\nThe study serves to point out the need for further, rigorous, study designed to answer the many questions that remain about ketamine for TRD, such as optimal dosing and route of administration, dosing interval and treatment length, and long-term effects\u2014just to name a few.\"\n\"Although ketamine is potentially a huge breakthrough in the treatment of depression, we still don\u2019t know about the long-term safety, or about how to keep people well from depression without requiring regular ketamine dosing,\" Stone added.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It does not appear that the story relied on a news release.", "answer": 1}, {"article": "Lorch also pointed out that this study involved a mostly homogenous population in a country outside the U.S.\n\n\"We should see whether similar effects are seen in higher-risk populations, such as the low socioeconomic population, racial and ethnic minorities and those at higher risk for neurodevelopmental delay,\" Lorch said.\nBut Rabe said these infants may actually benefit most from the practice.\nIt is unclear whether the practice could harm infants' health.\nRabe's editorial accompanied the study published Tuesday in the journal JAMA Pediatrics.\nMuch of the research has focused on preterm infants, who appear to benefit most from delayed cord clamping, Rabe said.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not rely solely on a news release.", "answer": 1}, {"article": "\"We try to time the pattern to stimulation so that it's integrated with their ability.\nDue to his improvements, the research team is developing a system that McGlynn can use at home and outside.\nNathan Makowski, an investigator at the Cleveland FES Center, created by Case Western Reserve and the Cleveland VA, said that FES technology has been used primarily for therapy in stroke patients in the past.\nTraining with the system improved McGlynn's speed when it was turned off to 23 yards per minute, indicating therapeutic benefit.\n\"I went in there and I could barely take two steps,\" said Bush, 42, who researchers believe is the world's first MS patient to \"test-drive\" an implanted FES system.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release doesn\u2019t rely on sensational language. However, the headline could easily mislead casual readers into thinking that nerve stimulation could help all MS and stroke patients improve their ability to walk, when in fact this specific technology was tested on just two patients.", "answer": 1}, {"article": "\u2022 In clinical trials, a plant-based vegetarian diet lowers LDL cholesterol by 12.2 mg/dL and reduces HDL cholesterol by 3.4 mg/dL, compared to control groups following an omnivorous, low-fat, calorie-restricted, or a conventional diabetes diet.\nWhat I've found is that if you want your patients to make significant health changes, you have to make them yourself.\nThe meta-analysis appears as an online advance in Nutrition Reviews.\nCharles Ross, D.O., a member of the nonprofit Physicians Committee and a former emergency department physician, has firsthand experience with putting a plant-based diet into practice.\nWithin a year, Dr. Ross traded a 34-year career of practicing emergency medicine for a new career path: lifestyle medicine.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "Overall, the release did not raise any of our red flags for sensational language. However, caution should be exercised before making statements such as that found in the physician testimonial:\n\u201cWithin the first month of making the dietary change, he effortlessly lost 10 pounds.\u201d\nLosing weight by making and sustaining dietary changes is rarely an\u00a0effortless\u00a0process. It takes time, commitment, and often, social support from family and friends. This characterization can be misleading for readers.", "answer": 1}, {"article": "Diffuse large B-cell lymphoma is the most common type of non-Hodgkin lymphoma in adults.\nArmin Ghobadi, an oncologist at Siteman who was an investigator in the Kite trial, said the new treatment is \u201cjust the first step\u201d and that researchers are working to make it safer and more effective.\nHe said the therapy already has been life-changing for many of his patients \u2014 and for him.\nEven so, Yescarta's cost is likely to stoke the ongoing debate about high drug prices.\n\u201cThese are patients who knew they were out of options,\u201d he said, noting that lymphoma patients who relapse or don't respond to treatment have just a 50 percent chance of surviving for six months.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Many of the facts and some of the quotes in the story come from the news release put out by the FDA, but there were enough unique details to give the story a pass in this category.", "answer": 1}, {"article": "Obesity puts children at greater risk of developing preventable conditions like heart disease and diabetes at a younger age, and suffering poor health later in life.\n\"Although these initial findings indicate that vitamin D could be used in the treatment of obesity, there remains a lack of evidence on the safety and long-term effects of supplementation, particularly if there is no vitamin D deficiency,\u201d said Charmandari.\n\"Future studies should explore what the underlying mechanisms are that explain this specific relationship between vitamin D and visceral adipose tissue.\"\nIt's encouraging that a simple intervention could have these effects and this certainly merits further investigation to consider its potential impacts on vitamin D supplementation for children with obesity.\"\nIn their next investigation, the team will study whether vitamin D supplements can improve the health of obese children and adolescents who have been diagnosed with disorders linked to obesity, such as high cholesterol, high blood sugar levels, and high blood pressure.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Some quotes used in the story match word-for-word what we found in a press release published by the European Society for Pediatric Endocrinology. Although there was outside expert commentary woven into the story, not mentioning or even linking to the release is a no-no if you are trying to be transparent about sourcing and helpful to readers.\nFor example, this quote appears in the Newsweek story, and is not attributed to the news release:\n\u201cThese findings suggest that simple vitamin D supplementation may reduce the risk of overweight and obese children developing serious heart and metabolic complications in later life.\u201d", "answer": 0}, {"article": "The remaining subjects were divided randomly into four groups.\n\"Little is said about rehabilitation or ways of helping patients recover pre-operative cognitive function.\"\nBefore that, older patients were rarely subjected to major surgery, and significant research in this field has only been conducted for approximately 15-20 years.\nOne of the obstacles to reliable diagnosis and rehabilitation is a lack of practical and secure instruments for pre- and post-operative cognitive assessment.\nThe earliest trials with patients who developed POCD were performed after the 1950s.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release uses responsible language to discuss the findings, although it could have been more clear about the preliminary nature of the work. A larger study is almost certainly called for on this intervention.\nWe do have some concerns over the use of the acronym \u201cPOCD\u201d to describe cognitive dysfunction following anesthesia. It appears to be a coined medical term that few clinicians use.", "answer": 1}, {"article": "Trans fats raise bad cholesterol, lower good cholesterol and ultimately increase the risk of heart attacks and strokes.\n\u201cHere we find on a population level when we restrict them, it benefits society by reducing heart attacks and strokes.\u201d\n\nThe findings suggest the FDA\u2019s action will lead to health benefits across the country, he added.\nWhen they removed New York City data to make sure those other factors weren\u2019t driving the findings, the pattern didn\u2019t change.\n\u201cNew York City was progressive and they enacted restrictions on trans fats, but no one looked to see if this made measurable changes to outcomes,\u201d said study lead author Dr. Eric Brandt, of Yale University in New Haven, Connecticut.\nBrandt told Reuters Health that New York City was also pushing other public health initiatives around the same time.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "A news release was made available\u00a0by Yale University, but this story offers a level of detail that far exceeds that.\n\u00a0", "answer": 1}, {"article": "It usually starts as a rash on one side of the face or body, often causing pain, itching and tingling.\nThe CDC has more on the shingles vaccine.\n\"It does bolster our confidence that it's effective in the real world,\" said Dr. Bruce Hirsch, an attending physician in infectious diseases at North Shore University Hospital in Manhasset, N.Y., who was not involved with the study.\nThe findings are published in the Jan. 12 issue of the Journal of the American Medical Association.\n\"This study helps me in terms of advising patients and prioritizing,\" Hirsch added.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "\n\n\nThe story does not appear to rely on a news release.", "answer": 1}, {"article": "Tucatinib is a small molecule inhibitor of the HER2 growth factor receptor.\n'There are women who are alive today because of this drug,' says University of Colorado Cancer center researcher\n\nPhase 1 clinical trial data published this week in the journal Clinical Cancer Research show early promise of the investigational anti-cancer agent tucatinib (formerly ONT-380) against HER2+ breast cancer.\nWorking with Borges's Young Women's Breast Cancer Translational Program at CU Cancer Center, young investigator Elena Shagisultanova, MD, PhD, recently earned a $1.4m competitive ASPIRE grant from Pfizer, Inc., to conduct a clinical trial exploring the use of tucatinib against so-called \"triple positive\" breast cancer - those cancers driven by both estrogen and progesterone receptors and the HER2/neu oncogene.\nThese data led to two subsequent Phase Ib studies, resulting in tucatinib earning FDA fast-track status and the expansion of this study once meant only to demonstrate drug safety into the \"pivotal\" trial that will determine approval.\n\"Tucatinib could be a substantially practice-changing drug,\" Borges says, meaning that in addition to the drug's current investigations as a third-, fourth-, or more-than-fifth-line treatment, she envisions its use sooner in the arc of breast cancer treatment and with far more patients.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The use of unjustifiably glowing language arguably is the news release\u2019s most serious\u00a0flaw. In particular, the subhead of the release quotes Dr. Borges as saying, \u201cThere are women who are alive today because of this drug.\u201d Later in the release, she predicts that tucatinib \u201ccould be a substantially practice-changing drug.\u201d While either statement could be true, drawing such sharp conclusions from evaluations of 35 women, only three of whom actually experienced tumor shrinkage, seems premature.\nIn addition, the investigator is quoted saying, \u201cAnd it\u2019s going to be an especially important drug due to its ability to control brain metastases\u201d\nIt\u2019s important to note the comments about crossing the blood brain barrier that come from the \u201cTranslational Relevance\u201d section of the study. The authors note that in preclinical studies with intracranial tumor models, mice treated with the investigational drug combined compared with 2 other oral agents (lapatinib or neratinib) showed a survival benefit when each drug was given at maximum dose. They do not note any study or evidence showing that this investigational agent has shown benefit in terms of treating brain metastasis in human patients, so that language in the release also appears unjustified.\nBecause it seems tucatinib would be used for a particularly vulnerable group of women \u2014 those diagnosed at younger ages and with more aggressive and difficult-to-treat cancers \u2014 it seems especially important that those writing about the drug exercise caution and avoid overplaying study results.", "answer": 0}, {"article": "In the U.K., women are advised not to drink at all during the first trimester of their pregnancy and to drink no more than a drink or two a week after that.\nIndeed, many of the women included in the \"light drinkers\" group had no more than a drink or two during their entire pregnancy.\nMore than 11,500 children and their mothers were included in the study.\nMothers were first asked about their alcohol use when the kids were 9 months old.\nThe children were last given a battery of behavioral and cognitive tests when they were 5 years of age.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story did not rely on a news release.", "answer": 1}, {"article": "The I.V.\nA longitudinal study would be needed to back those claims with evidence, she added.\nOne didn\u2019t turn up any significant improvement in patients who received the infusions.\nThe author, Dr. Alan Gaby, has long promoted the use of intravenous vitamins for a wide range of clinical conditions.\nSchwartz, though, said the supplements are completely safe.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story did not appear to rely on a news release, and quoted independent sources.", "answer": 1}, {"article": "Mammography with ultrasound spotted 78 percent.\nA mammogram had missed her cancer, CBS News medical correspondent Dr. Jon LaPook reports.\nFortunately, her doctor had an extra tool to screen her for breast cancer - an ultrasound.\nDoes it cross her mind what would have happened if she didn't have the ultrasound?\nDoctors caught and treated Fields' cancer early.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story has some independent reporting and information does not appear to be taken from a press release.", "answer": 1}, {"article": "Dr Gorlanova said: \"As research in this field progresses, we are understanding more and more about the gene-environment interaction for the development of asthma.\nIt is already known that environmental factors have a modifying effect on specific genetic risk, so the aim of this new study was to find out whether this could also be true for breastfeeding and this specific gene related to asthma with the respect to respiratory symptoms in early infancy.\nThis is the first time that we were able to show the effect of the 17q21 variants on respiratory symptoms during the 1st year of life, depending on breastfeeding status.\n\"Our study is the first to show that breastfeeding can modify the effect of asthma-related genetic profiles on respiratory symptoms in the first year of life\", commented Dr Olga Gorlanova, from the University Children's Hospital Basel (UKBB), and the University of Basel, Basel, Switzerland.\nFindings revealed that during the weeks that infants were breastfed, those carrying the asthma risk genotypes, had a 27% decreased relative risk of developing respiratory symptoms.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release doesn\u2019t employ sensationalistic language, however, as noted above, some statements may not have been justified based on the other information provided. \u201cInfants who have a genetic profile linked with asthma risk could be protected against respiratory symptoms if they are breastfeed [sic]\u201d and\u00a0\u201cOur study is the first to show that breastfeeding can modify the effect of asthma-related genetic profiles on respiratory symptoms in the first year of life.\u201d What the study did show was a 27 percent relative risk reduction in children who were breastfed as compared to a group who were not.", "answer": 1}, {"article": "CHICAGO -- The diabetes drug Actos was able to slow the progression of plaque buildup in artery walls, while an older diabetes drug failed to stop the progression in patients with diabetes and coronary-artery disease, according to a study released Monday.\n\nUntil now, no diabetes-therapy regimen has been shown to reduce the progression of coronary atherosclerosis within the arterial walls among patients with Type 2 diabetes, a disease characterized by high blood-glucose levels that result from the body's inability to use insulin.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There is no way to know if the story relied on a press release as the sole source of information.", "answer": 2}, {"article": ".\nIt must be empathized that this pathology affects more than 5 million in Spain, between 10% and 20% of the population, mostly women, and almost 100% of these being elderly , .\nIn this context, the phase III \"Helix\" study is being carried out in more than 30 hospitals in Spain, Germany, Estonia, Portugal, Slovakia and Italy, in 300 patients to evaluate the efficacy of this compound in the treatment of the sign and symptoms of dry eye syndrome.\nIn this context, Sylentis has participated at this event presenting the pre-clinical and clinical results of various compounds that are being developed for the treatment of ocular disorders.\nNon-clinical studies conducted by Sylentis with SYL1001 have demonstrated it has high ability to inhibit this specific target and block the perception of ocular pain in animals3.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The unjustifiable use of the terms \u201cdry eye disease\u201d and \u201cdry eye syndrome\u201d have already been addressed under the Disease Mongering criteria.", "answer": 1}, {"article": "Kobayashi said that some patients really hoped to continue rTMS after the study because their pain worsened after rTMS treatment sessions were over, and almost all the patients said that after the study ended, their pain increased to the level before rTMS.\nThe patients\u2019 pain scores were measured just before each weekly session.\nIn this second phase, the 18 patients underwent 12 weekly rTMS sessions.\nThe study participants had all been treated medically after a blood clot or bleed in one side of the brain (unilateral ischemic or hemorrhagic stroke).\nPain relief was sustained in six patients who continued treatment for one year.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "There wasn\u2019t any evidence of \u2018over-the-top\u2019 exaggeration of the findings of this study.", "answer": 1}, {"article": "The weight range was 38 to 173 kg (mean weight: 68.7 kg) and mean BMI was 25.3 kg/m2 (range 15.2\u201357.6 kg/m2).\nWhen Kyleena is removed, menstrual periods should return.\nFor some women, periods will stop altogether.\nWHIPPANY, N.J., Sept. 19, 2016 /PRNewswire/ -- Bayer announced today that the U.S. Food and Drug Administration (FDA) approved Kyleena\u2122 (levonorgestrel-releasing intrauterine system) 19.5 mg, a progestin-containing intrauterine system (IUS), for the prevention of pregnancy for up to five years.1 Kyleena will be available by prescription only in October 2016.\nAfter using Kyleena for a while, the number of bleeding and spotting days is likely to lessen.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release doesn\u2019t engage in sensationalistic language.\nThe release may be slightly out-of-bounds, however, when it states, at the top, that \u201cKyleena offers women an important new long-term, reversible contraception option.\u201d\u00a0 Who decides what makes something \u201cimportant\u201d? It\u2019s a tricky question. Based on the limited information in the release, it\u2019s not clear that the term applies here or that the product offers significant differences from other products already on the market.", "answer": 1}, {"article": "Using the Clinformatics Data Mart, a database of one of the largest commercially insured populations in the U.S., Baillargeon and colleagues examined data of 450 men aged 40 to 63 with COPD who began testosterone replacement therapy between 2005 and 2014.\nThe paper is currently available in Chronic Respiratory Disease.\n\"However, we are the first to conduct a large scale nationally representative study on this association.\"\n\"The findings suggest that testosterone replacement therapy may slow the progression of disease in men with COPD.\"\nThe goal of the study was to find out whether testosterone replacement therapy reduced the risk of respiratory hospitalizations in middle-aged and older men with COPD.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "There are no examples of egregious and unjustified language here.", "answer": 1}, {"article": "For the study, researchers led by Dr. Xiang Gao, of Brigham and Women's Hospital and Harvard University School of Public Health in Boston, analyzed data on more than 38,000 men and almost 91,000 women enrolled in the Health Professionals Follow-up Study and the Nurses' Health Study in 1994.\nThe study had some limitations, the authors acknowledged.\nIt's thought these drugs may have potent anti-inflammatory effects, which could protect the brain.\n\"There is no clear verdict,\" said Dr. Stuart Isaacson, director of the Parkinson's Disease and Movement Disorders Center of Boca Raton, who was not involved in the study.\n\"Right now we don't have any good evidence that there is anything we can do to reduce the risk of developing Parkinson's disease, but research is ongoing,\" added Isaacson, also an associate professor of neurology at Florida International University's Herbert Wertheim College of Medicine in Miami.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not rely on a press release.", "answer": 1}, {"article": "(Adenoids, glands at the roof of the mouth, are often removed along with tonsils.)\nAlso, there was limited research on long-term results.\nThere aren't strong guidelines regarding the use of tonsillectomy to treat sleep disorders, so the doctors reviewed the evidence to see whether the surgery outperformed so-called watchful waiting -- monitoring the situation.\nTo qualify for the surgery, a child must have many recurring throat infections within a short span of time or severe sleep disturbances, said Dr. Sivakumar Chinnadurai, a co-author of the reviews.\nBy the third year, there was no clear benefit in terms of the number of throat infections.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not appear to be based on a news release.", "answer": 1}, {"article": "Alcohol is known to activate some of the same receptors in the brain that opioids do, and studies find that by tempering the pleasure from alcohol, naltrexone can help people drink less.\nNaltrexone is certainly not a cure-all, researchers say.\nAnd it won't help everyone who has a drinking problem \u2014 especially if the disorder is severe.\nHe says that when used alone the medicines are only modestly effective.\nThat was exactly John's experience.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not appear to rely on a news release.", "answer": 1}, {"article": "Psoriasis is a chronic autoimmune-related skin condition in which thick, scaly patches appear on the skin.\nFurther analysis showed those who lost the most excess weight a year after surgery showed the biggest improvements in their disease activity.\nPatients who saw the most improvements had more severe disease at the time of surgery and were of an older age at diagnosis.\nPatients were on average monitored for more than six years, with an average excess weight loss of 46.2 percent body weight.\n\"These findings can be used to identify people who may benefit most from this type of intervention.\"\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The language is generally appropriate, and hasn\u2019t exaggerated\u00a0the effects of the bariatric surgery.", "answer": 1}, {"article": "University of Eastern Finland, Institute of Public Health and Clinical Nutrition, tel.\nLower consumption levels were not associated with the risk.\nApproximately 2,000 men participated in the study.\nHowever, research into the topic remains scarce.\nThe new study provides further evidence on the health benefits that fermented dairy products may have over non-fermented ones.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "No overtly unjustifiable language was used.\nWe appreciate mention of the fact that the possible mechanisms for explaining the study\u2019s findings are not completely understood.", "answer": 1}, {"article": "Renal vein surgery can often be managed with minimally invasive laparoscopic techniques, but this is not typically advisable for an IVC thrombus (a fibrous clot), which is surgically far more complex with potentially fatal complications that can occur in the course of removing the thrombus and reconstructing the IVC.\n\"Using robotic nephrectomy, our complication rate and lack of mortalities compare reasonably with open series with no grade III to V complications, according to the Clavien system, in any patient, including no deaths.\"\nEach surgeon performed between one and ten procedures for IVC tumor thrombi which ranged from one to 11 cm in length on preoperative imaging.\nThe first known procedure using robotic surgery of renal tumors with IVC tumor thrombi was performed in 2008.\nNone of the operations was converted to open surgery and all but two patients were ambulatory on the day of or day after surgery.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "\u201cRemoval of complex renal tumors performed safely by robotic surgery in selected patients,\u201d trumpets the headline. But nowhere do we learn what \u201csafely\u2019 means.\nThe lede says that \u201crobotic\u00a0nephrectomy for inferior vena cava tumor thrombus has favorable outcomes and reproducibility when performed by surgeons with adequate robotic experience,\u201d but then fails to tell us what \u201cadequate robotic experience\u201d means.\nThat is a fair question, given that 32 cases were performed in nine centers, and at least one of the surgeons was responsible for 10 procedures. That leaves 22 for the other eight, or fewer than three per surgeon over a time span that began in 2008 and is only now being reported.", "answer": 0}, {"article": "\"Some will benefit in a very large way.\nWhy would a woman at normal risk of breast cancer want to get routine mammograms?\nSo should U.S. women continue to get routine mammograms?\nOn balance, this is about five to 15 of those 2,500 women screened.\"\nIt is not wrong to want a routine mammogram, and it is not wrong not to want one.\"\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "", "answer": 1}, {"article": "\u201cIf you can give [someone like Robison] an idea of what emotions may be hidden behind a voice or face, then it enables his brain, without TMS, to change the way he approaches life and people.\u201d\n\nNevertheless, Pascual-Leone acknowledges that these changes can be challenging as well as beneficial, as Robison describes.\nStill, for all the positive changes described in \u201cSwitched On,\u201d Robison\u2019s fourth book, there were negatives he was forced to deal with.\nIt didn\u2019t occur to me that most of the news out there, most of the emotion, is, if not bad, at least not all good.\nPeople close to him questioned whether the risk was worth it.\nYet it is more than a linear account of a life transformed by cutting-edge medical technology.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "This story was obviously written from an interview of the author and his doctor. It did not rely on a news release.", "answer": 1}, {"article": "US Department of Commerce, International Trade Administration, National Travel and Tourism Office.\nThe pre-specified primary endpoint was the amount of sleep time in the first two thirds of the night.\nThe clinical efficacy results reported today are from the JET8 Phase-III clinical study (3107) (the JET8 study).\nThe conference call will be broadcast simultaneously on Vanda's website.\nThe call will also be archived on Vanda's website for a period of 30 days.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release doesn\u2019t engage in blatantly unjustifiable language.  ", "answer": 1}, {"article": "In this study, these induced pluripotent stem cells were then directed toward a neural progenitor cell fate, known as induced neural progenitor stem cells, or iNPCs.\nThis work was supported by the Simon and Beathrice Apple Stem Cell Fund for Eye Research, the David and Janet Polak Foundation Stem Cell Core Laboratory; National Institutes of Health (R01 EY020488), Department of Defense (W81XWH-12-1-0617), Foundation Fighting Blindness and the Knights Templar Eye Foundation Inc.\nNewswise \u2014 LOS ANGELES (EMBARGOED UNTIL 7 A.M. EDT on APRIL 14, 2015) \u2013 An injection of stem cells into the eye may soon slow or reverse the effects of early-stage age-related macular degeneration, according to new research from scientists at Cedars-Sinai.\nThis protective layer prevented ongoing degeneration of the vital retinal cells responsible for vision.\nCurrently, there is no treatment that slows the progression of the disease, which is the leading cause of vision loss in people over 65.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The headline\u2019s use of \u201cmay soon reverse vision loss,\u201d Svendsen\u2019s quote saying they\u2019re \u201cclose to a time\u201d of treating humans, and the cavalier referral to the \u201cnext steps\u201d without explaining that means many more years of study, all support a rating of unsatisfactory in this category.\u00a0 Anytime a news release raises hopes for treatment of a now-untreatable disease, it has to live up to those expectations. \u00a0This one didn\u2019t.", "answer": 0}, {"article": "Allergan Inc. said that two large human tests of its Botox drug, best known for smoothing wrinkles, showed that periodic injections prevent headaches in adults who suffer from chronic migraines.\n\nEven though details of the study weren't released, the announcement, which surprised many physicians and investors, sent Allergan's shares soaring 11%, or $5.95, to $60.53 at 4 p.m. in New York Stock Exchange composite trading. Botox has been used to treat severe headaches for many years, but some researchers have long been skeptical...", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Because the study quotes multiple independent experts, the reader can assume the story did not rely on a press release as the sole source of information.", "answer": 1}, {"article": "The Merck drug boceprevir and Vertex Pharmaceutical\u2019s similar drug telaprevir are expected to win FDA approval within months, following phase III trials showing that both drugs boosted cure rates to around 70% when used with standard therapy.\nThe drugs will be used in patients with HCV genotype 1 -- the hardest to treat form of the viral infection.\n\u201cTriple-drug therapy represents a major advance in the treatment of hepatitis C for patients,\u201d he says.\nAdding one of the drugs to the current two-drug regimen of peginterferon and ribavirin will make the treatment of hepatitis C more complex, but it will also cure a lot more people, hepatitis C specialist Donald M. Jensen, MD, of the University of Chicago Medical Center, tells WebMD.\nResults from two phase III boceprevir trials are published in the New England Journal of Medicine.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not appear to be based on the press release.\n", "answer": 1}, {"article": "However, gluconate binds the zinc ion more tightly than acetate does.\nAccording to Dr. Hemil\u00e4, there is no justification for the popular phrase that \"there is no cure for the common cold\" because of the strong evidence that zinc lozenges can shorten common cold duration by over 30%.\nThus, zinc doses of over 100 mg per day do not seem to provide any more benefit.\nNevertheless, he also considers that \"the current evidence of efficacy for zinc lozenges is so strong that common cold patients should be encouraged to try them for treating their colds, but the patients should ascertain that the lozenges do not contain citric acid or its salt citrate.\"\nThe 12% difference between the average effects of the two kinds of lozenges was explained purely by random variation.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release doesn\u2019t rely on sensational or unjustifiable language. However, it comes close when the study author states that there\u2019s no justification for the popular phrase,\u201dthere is no cure for the common cold\u201d because of the strong evidence that zinc lozenges can shorten common cold duration by over 30%.\u201d A 30 percent reduction in cold duration is not necessarily a cure.", "answer": 1}, {"article": "Suits against tobacco companies have sought to force cigarette makers to pay for annual CT screens of former smokers.\nThe study will be published in the coming months.\nSuch an analysis is months away.\nDr. Henschke\u2019s research has been controversial because of its statistical methods and its financing, which included money from a tobacco company.\nBut one-quarter of those given CT scans were found to have anomalies, nearly all of which were benign.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "\n\n\nThe story is not based on a news release.", "answer": 1}, {"article": "In the case of microablative fractional CO2 laser surgery, a series of microscopic laser beams using fractionated energy penetrate the skin to remove old and damaged skin cells, intended to rebuild the vaginal pathway.\n\"This study adds to the literature on vaginal laser therapy for GSM.\nThe results of this small, retrospective, non-sham-controlled study demonstrated that this type of laser surgery was particularly effective in reducing the intensity of dyspareunia (painful sex) and dryness.\nStudy results are published in the article \"Microablative fractional CO2 laser for the genitourinary syndrome of menopause: up to 12-month results.\"\n\"Until more data are available, all treatment options, including lubricants, vaginal moisturizers, and FDA-approved vaginal and systemic hormone therapies, should be discussed with women who suffer from GSM to determine the best treatment option for them.\"\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release is unjustified in claiming that this observational study demonstrates effectiveness. It made the claim in the following paragraph:\nThe results of this small, retrospective, non-sham-controlled study demonstrated that this type of laser surgery was particularly effective in reducing the intensity of dyspareunia (painful sex) and dryness. It further demonstrated that four or five laser therapies may be superior in lowering the intensity of GSM symptoms compared with three laser therapies in both short- and long-term follow-up.\nThe last paragraph of the release somewhat moderates the hearty endorsement of the therapy.", "answer": 0}, {"article": "\u201cNot everything that is natural is safe,\u201d she said.\nFighting bacteria with drugs designed to kill them helps fuel the problem of antibiotic resistance if stronger bacteria can survive and evolve to become \u201csuperbugs.\u201d\n\n\u201cBut instead of always setting a bomb off to kill an infection, there are situations where using an anti-virulence method may be just as effective, while also helping to restore balance to the health of the patient,\u201d said Quave.\nFrom an ecological standpoint, Quave said, it makes sense that invasive weeds have a chemical advantage that may help protect them from diseases so they can spread more easily in a new environment.\nIts leaves and bark are used to treat wounds, ulcers, burns and skin infections, Quave said.\nThe plant extracts didn't harm the skin tissues or the normal, healthy bacteria found on skin.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There appear to be a few original quotes in the Post story, not found in the news release. But story doesn\u2019t provide much beyond the information that\u2019s in the news release, and in fact has verbatim quotes from the lead researcher\u2013which aren\u2019t attributed as coming from the news release. Example:\nThis passage from the news release:\n\u201cBut instead of always setting a bomb off to kill an infection, there are situations where using an anti-virulence method may be just as effective, while also helping to restore balance to the health of a patient.\u201d\nalso appears in the Post story:\n\u201cBut instead of always setting a bomb off to kill an infection, there are situations where using an anti-virulence method may be just as effective, while also helping to restore balance to the health of the patient,\u201d said Quave.", "answer": 0}, {"article": "\"The concept is very simple,\" Lee said.\nThe cargo is delivered by zapping the device with a small electrical charge that's barely felt by the patient.\nResearchers plan to start clinical trials next year to test this technology in humans, Sen said.\n\"This is difficult to imagine, but it is achievable, successfully working about 98 percent of the time.\nIn my lab, we have ongoing research trying to understand the mechanism and do even better.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "Use of the word \u201cbreakthrough\u201d in the release is unjustifiable. The breakthrough status in treating humans hasn\u2019t been established (or tested) and so the headline is misleading.\u00a0The title of the letter from which the news release is drawn is more restrained but very technical: \u201cTopical tissue nano-transfection mediates non-viral stroma reprogramming and rescue.\u201d The release should have been headlined with something between the two extremes that also highlights that this was animal research.", "answer": 0}, {"article": "For those with neglect, doctors typically prescribe cognitive rehabilitation, in which therapists teach skills and help the patient become more aware of the affected side of the body.\nHe said that larger studies at multiple treatment sites are needed to determine how helpful magnetic stimulation can be in stroke recovery.\nBut he was optimistic about the treatment\u2019s future.\n\u201cThey\u2019re less likely to become completely independent.\u201d\n\nMost of those patients can improve with therapy and exercises, she said, but the process is often slow, and keeping people in the hospital during it is costly.\nBut researchers said it\u2019s still unclear what types of patients might benefit from the treatment and by how much.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "This story clearly did not rely solely or largely on a press release.", "answer": 1}, {"article": "\"When a body gets used to having a chronic headache suppressor, the patient can experience a rebound in the absence of that suppressor.\nDr. Richard Lipton, director of the Montefiore Headache Center in New York City, described the findings as \"very dramatic.\"\nMandato stressed that no one in the study required sedation to undergo the procedure.\nSeven of the patients (about 6 percent) failed to get any benefit from the treatment, the investigators found.\nThe researchers acknowledged that this procedure is a temporary solution that would need to be repeated.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story is not based solely on this press release, although the language in both reports was similar. Original reporting was demonstrated through the quotes from the two doctors \u2013 Dr. Kenneth Mandato and Dr. Richard Lipton.", "answer": 1}, {"article": "But they can have large effects on muscles and joints, often making muscles work as much as 50 percent harder for the same movement and increasing stress on joints by a similar amount.\nThey added, though, that the research was inadequate for them to have confidence in those conclusions.\nHalf of them got inserts and the others, for comparison, did not.\nThe only indication seems to be that a comfortable orthotic might be better than none at all, at least for the activities of people in the military.\nThe findings were somewhat puzzling: While the group that used inserts had about half as many injuries \u2014 defined as pain that kept them from exercising for at least half a day \u2014 there was no obvious relation between the insert a soldier chose and his biomechanics without it.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The article did not appear to rely on a press release.\n\n \n", "answer": 1}, {"article": "Medicare typically follows USPSTF guidelines in determining coverage and the Affordable Care Act specifies that USPSTF recommendations rated at the strongest levels must be used as a floor for coverage for private insurers.\nThe report greatly expands the universe of people who should be screened to see if they need the medication to everyone over age 40 regardless of whether they have a history of cardiovascular disease.\nIn an opinion piece Sunday, Redberg and Mitchell Katz, deputy editor of JAMA Internal Medicine, advised everyone to take \u201ca step back\u201d and ask \u201cwhy this debate is so contentious.\u201d They suggest that the estimates of the benefits of statins may be inflated, that the drugs as an intervention are \u201cweak,\u201d and that the reports of adverse events are incomplete.\nThe 2013 ACC and AHA guidelines recommend an estimated 24 million more people should be on them.\nThe group also said that people with a 7.5 percent to 10 percent risk \u201cmay also benefit\u201d but did not definitively recommend they take them.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The presence of outside critique of these recommendations suggest there was a low reliance on the news release.", "answer": 1}, {"article": "\"The issue is, can you detect these in patients that don't have advanced cancer?\" Venook said. \"The answer is, we don't know.\" The numbers tested by the MD Anderson researchers -- 251 patients with pancreatic cancer (five of whom had very early lesions), 32 with chronic pancreatitis and 120 healthy controls -- aren't nearly large enough to draw such conclusions. And getting a clear answer, Venook said, would probably require lengthy and expensive studies on very large populations.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story includes comments obtained from an interview with an independent expert, and statements from a published editorial about the significance of the research.", "answer": 1}, {"article": "Previous recommendations from the Centers for Disease Control's Advisory Committee on Immunization Practices (ACIP) had previously called for nasal sprays, or live attenuated influenza vaccine (LAIV), not be used during the 2016-2017 flu season.\nThis study was funded by the Canadian Institutes for Health Research.\nPublished today in the scientific journal Annals of Internal Medicine, the study shows that the nose spray had a similar effect to the standard flu shot.\nThen, subsequently, it was no longer preferred and now not recommended at all.\nLoeb says his team will continue to study herd immunity with different vaccine formulations by vaccinating children.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release does not use any unjustifiable language.", "answer": 1}, {"article": "Anderson.\nJonsson, an associate professor of cancer epidemiology at Umea University in Sweden, could not pinpoint exactly why his findings differed from those of other studies.\nThe findings will no doubt do little to quell a controversy that has existed since the 1980s over the value of mammography screenings for women in their 40s.\n\"Mammography has been shown in study after study to reduce breast cancer deaths in women aged 40 to 49,\" Obel added.\nHe mentioned certain differences in methodology as a possible factor, as well as the possibility that mammographic techniques have improved over the years.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not appear to rely on a news release. However, it does appear to rely entirely on what was presented in a teleconference sponsored by the conference host organization.\u00a0 In the end, is that any different that relying on a news release?\u00a0 Was their any independent vetting of claims that took place?\u00a0 There\u2019s no evidence of that.\u00a0 We\u2019ll rule this not applicable. ", "answer": 2}, {"article": "After adjusting for factors that might play a role in dying, such as age, gender, ethnicity and common causes of death, the researchers found those taking statins lived longer than those who were not taking them.\nOne expert doesn't think sufficient evidence exists yet to take statins to prevent or treat cancer.\n\"We cannot, however, recommend statins for cancer prevention without a positive clinical trial.\"\nAt this time, people without high cholesterol should not be taking statins in the hope of warding off cancer or living longer with cancer, he said.\n\"There is little evidence that statins affect cancer risk or survival, but clear evidence that they can help some people lower risk of heart attacks and strokes,\" he said.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Because the story includes quotes not found in the news release, this is satisfactory. But it is ironic that a closer reading of the news release might have helped the authors avoid a mistake.", "answer": 1}, {"article": "More than six million children in the United States have asthma, according to the Centers for Disease Control and Prevention, as do more than 330 million children and adults worldwide, according to the Global Asthma Network.\nAn editorial in the same journal by an expert who was not part of the study praised the research, saying it was well designed and carefully performed.\nThe research was paid for by the Danish government and private foundations.\nThe scientists bought fish oil from a company that makes it, but they said the company had no role in the study.\nDr. Bisgaard said it was not possible to tell from the study whether pregnant women could benefit from simply eating more fish.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "This story did not rely on the news release.", "answer": 1}, {"article": "Compare that with a decrease of about 7 mg/dL for the low-fat diet, and about a 8 mg/dl drop from the moderate-fat diet.\nIt was also supported by a grant from the Hass Avocado Board, an industry group that the researchers say had no role in the design of the study or the interpretation of the data.\nTheir study was published Wednesday in the Journal of the American Heart Association.\nWe asked Kris-Etherton if she would have published the results had there been no positive findings for the avocado.\nIn one sample meal plan, lunch was chicken salad with half an avocado, and dinner included turkey tacos with another half an avocado.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It was clear, based on multiple quotes in the story, that the reporter spoke at length to a researcher involved with the study, rather than relying solely on the news release.", "answer": 1}, {"article": "Drs.\nBupropion should be considered the first-line drug of choice for people who are overweight or obese, Dr. Simon said.\nBut patients should consult their doctor about which medication is right for them, before making any changes, including starting, switching, or stopping medication.\n\"So it makes sense for doctors and patients to choose antidepressants on the basis of their side effects, costs, and patients' preferences--and, now, on whether patients are overweight or obese.\"\n\"A large body of evidence indicates no difference in how effectively the newer antidepressants improve people's moods,\" said Dr. Arterburn's coauthor Gregory Simon, MD, MPH, a Group Health psychiatrist, GHRI senior investigator, and research professor in psychiatry and behavioral sciences at the UW School of Medicine.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release doesn\u2019t rely on unjustifiable language. We would underscore the study author\u2019s comment that \u201cbupropion is the best initial choice of antidepressant for the vast majority of Americans who have depression and are overweight or obese\u201d by adding that each individual needs to be evaluated for their symptoms with a medical professional making a recommendation on the appropriate drug therapy.", "answer": 1}, {"article": "Greek researchers offered fresh evidence of the health benefits of the Mediterranean diet, reporting in a large study that it helps improve several risk factors linked to diabetes, obesity and heart disease.\n\nThe Mediterranean diet is high in monounsaturated fats such as olive oil and also relies heavily on whole-grain cereals, fruits and vegetables, fish and low consumption of animal fats. It has been shown in numerous studies and clinical trials to reduce mortality from such causes as cardiovascular disease and cancer.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It\u2019s clear that the story does not rely solely on a news release.", "answer": 1}, {"article": "ASTRO publishes three medical journals, International Journal of Radiation Oncology\n\u2022 Biology\n\u2022 Physics (www.redjournal.org), Practical Radiation Oncology (www.practicalradonc.org) and Advances in Radiation Oncology (www.advancesradonc.org); developed and maintains an extensive patient website, RT Answers (www.rtanswers.org); and created the Radiation Oncology Institute (www.roinstitute.org), a nonprofit foundation to support research and education efforts around the world that enhance and confirm the critical role of radiation therapy in improving cancer treatment.\n\u201cThis study illustrates that a potentially curative dose of radiation may be delivered safely to the prostate entirely in a single administration,\u201d said Dr. Krauss.\n\u201cGiving the entire dose in a single treatment theoretically could have had a greater negative impact on the normal tissues in close proximity to the prostate\u2014meaning the bladder, urethra and rectum\u2014but this was not found to be the case.\nToxicity rates were extremely low, with essentially no major complications encountered in this initial group of 58 patients.\u201d\n\nWhile findings highlight the potential tolerability of a single fraction of HDR brachytherapy for localized prostate cancer, the article also emphasizes the need for additional follow-up to compare long-term cancer control rates with conventional treatment approaches, which generally administer larger cumulative doses than the 19 Gy dose used in this trial.\nIn this study, researchers found that patients who received a single fraction of 19 Gy HDR brachytherapy experienced similar clinical outcomes as with LDR brachytherapy, but with the convenience of a single visit.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release detracts from the actual study when it states that the research \u201cillustrates that a potentially curative dose of radiation\u2026\u201d \u00a0This seems unjustified in the context of the trial. Is one ever really \u2018cured\u2019 from prostate cancer?\nGiving caveats, yet dropping the line that \u201cthe single-treatment approach can eventually become a standard practice for prostate cancer treatment,\u201d seems premature.\nUrologist Willet Whitmore, MD, a founder of the urology oncology sub-specialty, spoke about localized prostate cancer cures this way:\u00a0\u201cIf treatment for cure is necessary, is it possible? If possible, is it necessary?\u201d", "answer": 0}, {"article": "Women choosing to have both breasts removed face higher surgery costs and slightly higher risks of post-surgery complications and infections.\nBoth Leach and Tuttle are pursuing research studies to address the why question.\nThe survey results came a decade ago, however, when the safety of breast implants was a major issue, said Mayo\u2019s Dr. Lynn Hartmann.\nU researchers confirmed the trend using federal cancer data but could only speculate why.\nFor other women, a double mastectomy might eliminate another breast cancer, but it won\u2019t stop cancer from resurfacing in vital organs, Tuttle said.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There is no evidence that the report relies on the journal\u2019s press release. ", "answer": 1}, {"article": "PHILADELPHIA - According to a new study, women experiencing difficulty with time management, attention, organization, memory, and problem solving - often referred to as executive functions - related to menopause may find improvement with a drug already being used to treat attention deficit hyperactivity disorder (ADHD).\nResults of the study are published online today in the journal Psychopharmacology.\nIn addition to Epperson, other Penn co-authors are Sheila Shanmugan, Deborah R. Kim, Sarah Mathews, Kathryn A. Czarkowski, Jeanette Bradley, Dina H. Appleby, Claudia Iannelli, and Mary D. Sammel.\nTherefore, promoting healthy cognitive aging among menopausal women should be a major public health goal.\"\nThe Penn-led team administered a once-daily dose of LDX for four weeks to 32 healthy, non-ADHD-diagnosed women between the ages of 45 and 60 experiencing difficulties with executive functions as a result of mid-life onset menopause, and as measured using the Brown Attention Deficit Disorder Scale (BADDS).\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "As noted above, we don\u2019t think it\u2019s well documented how \u201ccommonly experienced\u201d these cognitive complaints really are, to the point they interfere with life or functioning. However, since we\u2019ve already dinged the story for that problem and there aren\u2019t any egregious overstatements, we\u2019ll award a Satisfactory grade.\n\u00a0", "answer": 1}, {"article": "\"This is a small study, but also very intensive with direct, accurate pressure measurements,\" Moon said.\nHe also said research is ongoing to further illuminate the causes of SIPE and potential ways of diagnosing it early.\n\"Some cases of SIPE appear to have been the result of cardiac problems,\" said Moon, who was lead author of the study published online February 16 in Circulation: Journal of the American Heart Association.\nMoon said larger studies are needed to replicate the results and learn more about possible adverse side effects of the drug.\nMoon and colleagues studied these responses in 10 athletes who had experienced the condition while exercising or competing in triathlons.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "We found no language in the release that was clearly out of bounds. As noted above, however, we\u2019re concerned that cautionary language is overwhelmed by an enthusiastic testimonial from a swimmer who believes she has benefited from using the drug.", "answer": 1}, {"article": "For example, psoriatic arthritis manifests most often in the lower extremities and is associated with the autoimmune skin condition called psoriasis, in which raised red, scaly patches appear on the skin.\nLilly has filed for approval of the drug by the U.S. Food and Drug Administration.\nAlthough the ultimate cause of the disease remains unknown, there was a good clinical rationale for hoping it might be responsive to ixekizumab.\nFor the last decade or so, Genovese said, another pro-inflammatory substance called IL-17 has been drawing the attention of immunologists focusing on psoriasis and psoriatic arthritis.\nThe drug, an injectable monoclonal antibody, is already commercially available for the treatment of psoriasis, for which it has been remarkably effective, said Genovese.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "There are no examples of unjustified language.", "answer": 1}, {"article": "Pregnancy experts, including those at the American College of Obstetricians and Gynecologists, recommend that most pregnant women get 30 minutes of exercise a day.\nThe Baylor scientists were able to correct for those variables.\nHow does this relate to our own species?\nThe research in question involved mice, not women.\nThe mice with running wheels voluntarily ran an average of more than six miles a night, decreasing to about two miles late in pregnancy.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "This brief story is highly reliant on a news release. \u00a0The reporter has made no obvious attempt to contact the researchers for further information or to obtain reactions from other scientists.", "answer": 0}, {"article": "Jay Konduros used to rush home several times a year after accidentally cutting or bumping himself.\nThe treatment also \u201cnearly universally eliminated\u201d the need for preventive infusions of clotting factor a few times a week, the scientists said.\nThe results, published Wednesday online in the New England Journal of Medicine, represent \u201canother example of the gene-therapy renaissance,\u201d Matthew Porteus, a pediatrician at Stanford University, wrote in an accompanying editorial.\nThe follow-up period was relatively short, from 28 to 78 weeks in the new report; longer-term studies are needed to prove safety and effectiveness over extended periods.\nThe researchers presented earlier findings on the gene therapy a year ago at the American Society of Hematology's annual meeting, but the latest data covers a larger patient group and a longer time period.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "A news release issued by Children\u2019s Hospital of Philadelphia did a good job of describing this study; the Post story could have picked up more of the salient details from that text but reveals independent reporting nevertheless by including sources not connected to the study.", "answer": 1}, {"article": "Researchers said no Aimovig patients stopped treatment due to side effects, while around 1 percent of placebo patients discontinued because of side effects.\nReuter said the 17-point gap between the treatment and placebo groups was in line with previous Aimovig studies.\nHe said previous studies excluded patients who had tried more than two other treatments.\nThe drug, a monoclonal antibody, was given monthly by injection at a dose of 140 mg for the trial.\nThe 12-week trial, presented this week at the annual meeting of the American Academy of Neurology, involved 246 patients suffering four to 14 migraine headaches a month who had tried two to four preventive treatments that either did not work for them or had intolerable side effects.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "While most of the information in the article is taken from this news release, the story is transparent about this. It also includes quotes from a telephone interview with the study\u2019s lead investigator, so we can be certain that at least some original reporting went into the piece.", "answer": 1}, {"article": "Sept. 28, 2010 -- Intrauterine devices (IUDs) -- used to prevent pregnancy -- may also be an effective treatment for some patients with early-stage uterine cancer who want to preserve their fertility.\n\nIn a small, early study, carefully selected patients with cancer that had not spread beyond the inner lining of the uterus were treated with IUDs that released the hormone progesterone.\n\nThe treatment was found to be as effective as oral hormone therapy, which is the most widely used nonsurgical, fertility-sparing treatment for the cancer.\n\n\u201cOur results show promise for the treatment of younger endometrial cancer patients with early disease who desire pregnancy in the future,\u201d gynecologic oncologist Lucas Minig tells WebMD. \u201cBut patients must be screened very carefully to make sure their disease has not spread.\u201d", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Because the story quotes one expert who is not affiliated with the study, the reader can assume that the story does not rely on a press release as the sole source of information.", "answer": 1}, {"article": "Unlike common polyps, they tend to be flat and the same color as the colon lining.\nSome of the study authors and the Mayo Clinic have a financial interest related to technology used with this research.\nThe DNA stool test methods were developed at the Mayo Clinic.\nTUESDAY, May 4, 2010 (HealthDay News) -- Noninvasive stool DNA testing can detect two types of colorectal precancers and could play a larger role in colon cancer prevention, say two new studies.\n\"This study shows that cancer and precancer in IBD can be detected noninvasively,\" senior investigator Dr. David Ahlquist said in a Mayo news release.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "All information and quotes appear to be drawn from a Mayo Clinic news release.\u00a0 There is no sign of any independent reporting. ", "answer": 0}, {"article": "1 in hospitals.\u201d\n\nAccording to the Centers for Disease Control and Prevention, C. difficile infects half a million people in the United States per year and kills 15,000 people.\nKao is one of the authors of the paper and a gastroenterologist at the University of Alberta.\nBut most importantly, the study found no difference in effectiveness between the two therapies.\nAn emerging treatment for a common hospital-acquired infection could be (slightly) less gross in the future.\nOther efforts to take the \u201cpoop\u201d out of the poop pills\u2014to just include the bacteria thought to be behind the benefits\u2014have failed.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It does not appear to rely on a news release.\n\u00a0", "answer": 1}, {"article": "Abbott Laboratories is betting heart patients will benefit from a new type of arterial stent that dissolves away when it is no longer needed.\n\nStents are scaffold-like devices used to prop open clogged heart arteries. Most stents are made of metal. But Abbott's new device, called Absorb, is made from a plastic-like material called polylactide that is commonly used in surgical sutures. The Absorb scaffold\u2014Abbott doesn't call it a stent\u2014is designed to completely fade away in two years and to cease supporting arteries at six...", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Since the story quotes an unaffiliated expert in the field of cardiac pathophysiology, it is clear that it did not rely solely on a press release.\u00a0We do wonder, however, why the story ran prior to the issuance of the preliminary results on the new study.", "answer": 1}, {"article": "Menopause is a normal part of a woman's aging process but pre-menopausal women treated with chemotherapy can also develop premature menopause, and consequently, severe menopausal symptoms including sleep disorders, vulvovaginal atrophy (VVA), vasomotor symptoms (VMS), mood changes, depressive symptoms, cardiovascular disease, osteopenia, and osteoporosis.\nThe study, \"Managing Menopausal Symptoms and Associated Clinical Issues in Breast Cancer Survivors\" is published online at https:/ , ahead of print.\nSanten and colleagues reviewed controlled clinical trials, observational studies, evidence-based guidelines, and expert opinion from professional societies to address the gap in treatment recommendations for management of menopausal symptoms after breast cancer.\nThe most important thing to remember is that therapy must be individualized based on each woman's needs and goals.\"\nThe Society has more than 18,000 members, including scientists, physicians, educators, nurses and students in 122 countries.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release did not use unjustifiable language.", "answer": 1}, {"article": "A capsule of Probiotic Immunity from New Chapter Inc., based in Brattleboro, Vt., contains 1 billion each of 10 different organisms, including Streptococcus salivarius subsp. thermophilus and Lactobacillus acidophilus, two species of bacteria often found in yogurt. Other ingredients include herbs such as cumin, ginger and spinach. Users are instructed to take two capsules each day, preferably one in the morning and one in the evening, on an empty stomach. You can buy a bottle of 90 capsules for about $20 at many health food stores.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It\u2019s clear that the story did not rely on a news release.", "answer": 1}, {"article": "Professor Paul Workman, Chief Executive of The Institute of Cancer Research, London, said:\n\n\"Nivolumab is one of a new wave of immunotherapies that are beginning to have an impact across cancer treatment.\nThis trial found that it can greatly extend life among a group of patients who have no existing treatment options, without worsening quality of life.\nMore than double the number of patients taking nivolumab were alive after one year as those treated with chemotherapy, reported the major international trial, published today (Sunday) in the New England Journal of Medicine.\nThis group of patients are expected to live less than six months.\nSome of the data was presented at 16:25 CEST today (Sunday) at the European Society for Medical Oncology 2016 Congress in Copenhagen.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "This is a weak point for the release. Vaguely exciting terms, such as \u201cgame changer,\u201d have no place in a news release that is discussing the lives of human beings. \u201cGame changer\u201d is a term that has no objective definition. One person may think that the possibility of extending life by two months is a \u201cgame changer.\u201d Another person may see the term \u201cgame changer\u201d and think that it must mean they\u2019ve found a new way to put head and neck cancer into remission. This could lead to disappointment when the findings are explained in detail.\nThe release states that the drug \u201cgreatly improves survival\u201d \u2014 and perhaps within the oncology community this may be appreciated as an improvement for this type of refractory cancer. But in patient terms we are talking months of survival. All of the study participants had died by 18 months.", "answer": 0}, {"article": "But another found that the stroke rate was 22 percent lower in people who ate chocolate once a week, and a third reported that death from stroke was 46 percent lower in those who ate 50 grams of chocolate once a week.\nThe health benefit may come from antioxidants called flavonoids that are present in chocolate, Saposnik said.\nBut the findings, based on a review of existing research, aren't conclusive, and they don't prove that chocolate is good for your heart.\nFor now, said registered dietitian Katie Clark, \"caution should be taken not to promote chocolate as a health food,\" even though it's fine in moderation.\nSaposnik said more studies will help clarify the association between chocolate and stroke risk.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Since several sources were quoted, it does not appear that the story relied solely on a news release. ", "answer": 1}, {"article": "We have to really ask the question: 'How low do you go?'\nAbout half the excess deaths were from heart disease.\nLetters were mailed to all participants Monday notifying them of the results so they could consult with their doctors about switching to the less intensive therapy.\nAlthough the reason for the increased risk remains a mystery, Nabel and other experts stressed that the benefits of blood sugar control have been well established for diabetics and said patients should not make any changes in their care without consulting their doctors.\nOfficials defended the study, saying previous research had suggested that intensive blood sugar lowering would be beneficial.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Does not appear to rely on a press release.", "answer": 1}, {"article": "While smoking is a public health scourge, the nicotine in cigarettes may have some promise in treating another growing problem, mild cognitive impairment (MCI), which can be a precursor to Alzheimer\u2019s disease or other forms of dementia.\nHowever, when clinical experts rated overall general change in the patients, they did not see a significant difference between the two groups.\nMORE: Is Nicotine a \u2018Gateway\u2019 to Cocaine Addiction (and Cancer)?\nThe study was led by Dr. Paul Newhouse of Vanderbilt University and published in Neurology.\nThe authors conclude, \u201cThis initial study provides evidence for nicotine-induced cognitive improvement in subjects with MCI; however, whether these effects are clinically important will require larger studies.\u201d\n\nThe study found no problematic side effects associated with the nicotine patch and none of the patients had withdrawal symptoms when it was stopped.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "As explained in the \u201cevidence\u201d criterion above, there were numbers used in this story and that by MSNBC that we couldn\u2019t find anywhere in the journal article but which did appear in in news releases by the American Academy of Neurology and by Vanderbilt. But it\u2019s clear that the story didn\u2019t rely solely on news release, as it brought in enough good contextual information, including the conflict of interest information and the information about nicotine and cancer.", "answer": 1}, {"article": "Lactoferrin supplementation also enhances the expression of salivary immune proteins, which may help reduce oxidative stress and resulting side effects.\nAlthough TSA is widespread and a frequent complaint of cancer patients, until now, there have been no established therapies that reliably prevent or treat this problem.\nThis research could help us develop TSA-targeted biomarkers and strategies for improving quality of life during chemotherapy.\n\"The prevailing symptom described by patients undergoing chemotherapy is a persistent metallic flavor or aftertaste, with or without food intake.\nTheir findings could bring relief to millions of patients undergoing cancer treatment.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "A preliminary study that relies heavily upon a highly subjective questionnaire completed by just 12 patients does NOT justify a headline/subhead like this:\n\u201cMilk protein shown to alleviate chemotherapy side effects: Findings could bring relief to millions of patients undergoing cancer treatment.\u201d\n\u201cOur results suggest lactoferrin may be developed as an effective dietary supplement to treat TSA caused by chemotherapy and increase the expression of salivary proteins.\u201d\nThis statement is barely supported by the data and the extrapolation made in the news release is completely unfounded.", "answer": 0}, {"article": "The procedure, called a prostatic urethral lift, does not improve flow as much as surgery, in which a physician cuts away some of the inside of the prostate to allow better flow. But the lift procedure and recovery are much quicker, with no hospital stay and fewer complications. And patients who get the sutures can always come back for surgery later.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not appear to rely on a news release, though positive anecdotal testimonials predominated the piece.", "answer": 1}, {"article": "\"We're not training them on one skill, like doing crossword puzzles,\" she says.\nCarlson notes that many cognitive intervention studies last one year or less.\nThe researchers were particularly interested in the results, considering that people with less education and who live in poverty are at greater risk for cognitive decline.\nOne strength of this study, she says, is that the participants were followed for two years, which in this case was long enough to see changes that wouldn't have been detected after just one year.\nThe control arm of the study, those not involved in Experience Corps, exhibited age-related shrinkage in brain volumes.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The suggestion that this study demonstrates \u201creversing part of the aging process,\u201d based on such a small subgroup of a small study, is an exaggeration.", "answer": 0}, {"article": "Kalluri and his colleagues examined serum samples from 190 patients with pancreatic cancer, 32 patients with breast cancer and 100 healthy volunteers.\nIt was not present in the healthy volunteers.\nAnd even if it passes muster, it will take some time before a test could be developed to screen for the disease.\nIt is a good example of how this disease sneaks up on people and gives no warning.\u201d\n\nA test for pancreatic cancer could save lives, perhaps even Flippo-Morton\u2019s, Raghavan said.\n\u201cSomething like this could potentially flatten that curve and change the epidemiology of pancreatic cancer.\u201d\n\nStill, Donahue said, the method needs to be \u201cheavily vetted and validated.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not rely on a news release.", "answer": 1}, {"article": "\"Historically, patients with chronic systolic heart failure were considered too frail to exercise and, through the late 1980s, avoidance of physical activity was a standard recommendation,\" the study's authors write.\nThe study authors say there's a usually a strong relationship between depression and heart failure, so the fact that tai chi helped cheer people up was an especially good sign.\nThe movement is tai chi, an ancient martial art turned exercise, and a study out this week in Archives of Internal Medicine says it may help people suffering from heart failure feel better about life.\nThe researchers recruited 100 people with the chronic condition from heart clinics in Boston.\nIn a quality of life questionnaire the researchers gave out, those who practiced tai chi scored significantly higher than those who hadn't been doing the movement.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story doesn\u2019t appear to have lifted anything from this press release put out by Beth Israel Deaconess Medical Center. (In fact, the release included many details that would have been useful to include in the story, but weren\u2019t covered.) Since the story includes no independent perspectives, however,\u00a0we can\u2019t be sure to what extent it may have relied on this or some other news release.", "answer": 2}, {"article": "Parkinson's is not considered an inflammatory disease, he said, adding: \"We might be missing something.\nTagliati called the study \"eye-opening.\"\nThe exact cause is unknown, but experts believe it's a combination of genetic and environmental factors.\n\"So it narrows the focus to a subgroup of [anti-inflammatory drugs].\"\nHe is scheduled to present the findings in Toronto at the annual meeting of the American Academy of Neurology in April.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "One independent source was quoted, so it\u2019s clear the story didn\u2019t rely solely on a news release.", "answer": 1}]